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6/j.bPrevention of relapse after allogeneic hematopoietic stem cell transplantation is the most likely approach to
improve survival of patients treated for hematologic malignancies. Herein we review the limits of currently
available transplant therapies and the innovative strategies being developed to overcome resistance to ther-
apy or to fill therapeutic modalities not currently available. These novel strategies include nonimmunologic
therapies, such as targeted preparative regimens and posttransplant drug therapy, as well as immunologic
interventions, including graft engineering, donor lymphocyte infusions, T cell engineering, vaccination, and
dendritic cell-based approaches. Several aspects of the biology of the malignant cells as well as the host
have been identified that obviate success of even these newer strategies. To maximize the potential for
success, we recommend pursuing research to develop additional targeted therapies to be used in the pre-
parative regimen or as maintenance posttransplant, better characterize the T cell and dendritic cells subsets
involved in graft-versus-host disease and the graft-versus-leukemia/tumor effect, identify strategies for timing
immunologic or nonimmunologic therapies to eliminate the noncycling cancer stem cell, identify more
targets for immunotherapies, develop new vaccines that will not be limited by HLA, and develop methods
to identify populations at very high risk for relapse to accelerate clinical development and avoid toxicity in
patients not at risk for relapse.
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The goal of allogeneic hematopoietic stem cell
transplantation (HSCT) is well established as long-a Farber Cancer Institute, Boston, Massachusetts;
of Texas, M.D. Anderson Cancer Center, Houston,
d Hutchinson Cancer Research Center and Univer-
hington, Seattle, Washington; 4U.S. Food and Drug
tion, Rockville, Maryland; 5Memorial Sloan-
ancer Center, New York, New York; and 6National
titute, Bethesda, Maryland.
re: See Acknowledgments on page 1061.
equal primary authors.
e and reprint requests: Edwin P. Alyea, MD,
er Cancer Institute, 44 Binney Street, Boston, MA
ail: edwin_alyea@dfci.harvard.edu).
, 2010; accepted May 14, 2010
an Society for Blood and Marrow Transplantation
.00
bmt.2010.05.005term disease-free survival (DFS). Recent improvements
in treatment plans and supportive care have reduced
treatment-related mortality, and disease relapse has
now emerged as the principle reason for treatment
failure after transplantation. As reviewed in a previous
workshop report [1], risk factors for relapse after trans-
plantation vary with the diagnosis of the underlying
malignancy, but patients transplanted not in remission
are at especially high risk for posttransplant recurrence
independent of diagnosis. Factors that influence the
duration of survival after relapse include age, perfor-
mance status, comorbidities, remission duration, tumor
burden at relapse, and presence of mixed chimerism.
With rare exception, however, posttransplant relapse
is ultimately fatal. Consequently, development of new
strategies to prevent relapse is imperative if survival of
transplanted patients is to improve.
Other workshop committees have provided detailed
reviews of potential and actual therapeutic targets based1037
Table 1. Potential Causes of Resistance to Therapy That May
Predispose to Relapse
Resistance to chemotherapy
Drug impermeable niche
Noncycling state
Altered function of drug transporters
Upregulation of DNA repair mechanisms
Upregulation of DNA damage sensing mechanisms
Upregulation of intracellular drug detoxifying molecules
Upregulation of intracellular drug degradation mechanisms
Dysregulation of apoptosis
Gain of function mutation of the target molecule
Amplification of the target molecule
Reduced activation of prodrug
Rapid metabolism of active drug
Resistance to radiation
Hypoxic niche
Noncycling state
Upregulation of DNA repair mechanisms
Upregulation of DNA damage sensing mechanisms
Dysregulation of apoptosis
Resistance to immunologic mechanisms
Microenvironment
Stromal barriers to chemokines
Local myeloid-derived suppressor cells (MDSC)
Local essential nutrient depletion
Tumor
Antigenic modulation or lack of a tumor specific antigen
Downregulation of MHC or costimulatory expression
Downregulation of death receptors
Resistance to perforin or granzyme
Expression of inhibitory ligands (FasL, PD-L, VEGF, KIR-L)
Production of soluble antigens
Production of immunosuppressive cytokines
Dysregulation of apoptosis
Immune system
Disruption of lymphoid architecture/trafficking
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and the biologic basis of the effector immune response
to hematologic malignancies [3]. Table 1 provides
a partial listing of potential mechanisms by which these
diseases may evade the potent actions of high-dose che-
moradiotherapy and the graft-versus-leukemia/tumor
(GVL/GVT) effect. The potential causes involve the
tumor microenvironment, the biology of the malignant
cell, the biology of the host including the immune sys-
tem, and exogenous factors. Some of these factors, such
as the cell cycle status, blood supply, or transcriptional
dysregulation, may be temporary, whereas the genetic
constitution is likely immutable.
In this manuscript, we discuss the current results
for conventional transplant therapies to identify the
barriers to disease control posed by these potential
resistance mechanisms. We also review the promising
innovative treatments designed to eliminate or circum-
vent these barriers. The areas of review include both
the nonimmunologic therapies, such as preparative
regimens and posttransplant drug therapy, aswell as im-
munologic interventions, including graft engineering,
donor leukocyte/lymphocyte infusions (DLI),T cell en-
gineering, vaccination, and dendritic cell (DC)-based
approaches. Finally, based on these data, we provide
our recommendations for critical strategies to prevent
relapse after transplantation and the challenges that
must be addressed to ensure success.Defective APC function
Development of Treg
Upregulation of inhibitory receptors (PD-1)
Exogenous factors
Concomitant use of immunosuppressive drugs
VEGF indicates vascular endothelial growth factor.PREPARATIVE REGIMENS
Allogeneic HSCT is a widely used form of therapy
for patients with hematologic malignancies. In 2009
alone, between 15,000 and 20,000 patients were treated
with this procedure worldwide. Although the proce-
dure is often effective, posttransplant relapse is a com-
mon occurrence. According to reports from theCenter
for International Blood and Marrow Transplant
Research (CIBMTR), relapse rates following adminis-
tration of ablative transplant preparative regimens and
human leukocyte antigen (HLA)-matched transplanta-
tion range from approximately 25% for good-risk
patients (acute leukemias in first complete remission
[CR] or chronic myelogenous leukemia [CML] in
chronic phase) to over 60% for patients transplanted
in relapse [4–6]. Efforts to decrease posttransplant
relapse rates have focused largely on intensification of
cytoreductive therapy, either by increasing the total
body irradiation (TBI) dose or adding additional or
alternative chemotherapy. Controlled randomized
studies have shown that relapse rates can be reduced
by increasing the TBI dose. A randomized trial in
patients with acute myelogenous leukemia (AML) in
first CR found that the relapse rate was 12% after
15.75 Gy, compared to 35% after 12 Gy [7]. A similar
study in patients with chronic phase CML found thatthe recurrence rate was 0% after 15.75 Gy, compared
with 25% after 12Gy [8]. However, in both these stud-
ies, the nonrelapse mortality (NRM) was increased
with the higher TBI dose, leading to no improvement
in overall survival (OS). Additional support for the
importance of the TBI dose has recently been demon-
strated in a retrospective study examining different
conditioning regimens for patients undergoing sibling
allografts for acute lymphoblastic leukemia (ALL) [9].
Similar to thefindingswithTBI, higher chemother-
apy doses in the preparative regimen have also been
shown to decrease relapse rates. Investigators from the
Fred Hutchinson Cancer Research Center studied 45
patients with chronic or accelerated phase CML who
received a preparative regimen consisting of busulfan
(Bu) and cyclophosphamide (Cy) and received trans-
plants fromHLA-identical related donors to determine
the influence of variations in Bu plasma concentration
on the rate of relapse [10]. Of 22 patients with steady-
state Bu levels below themedian, 7 developed persistent
cytogenetic relapse, and 3 of these patients died. In
contrast, there were no relapses in patients with Bu
Bu+Cy+TBI*
Bu+TBI*
Cy + TBI*
Flu + AraC
Bu + Cy (± ATG)
Bu + Melphalan
Flu + Melphalan
Flu + Bu (3.2-16)
TBI† + Flu (90-250)
TBI†
Intensity
yticix
oT
Required Contribution of GVT Effect
*TBI at ≥12 Gy;   2 cGy; 
Figure 1. Conditioning regimens for allogeneic HSCT (figure courtesy
of Deeg).
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in the hazard of relapse between the 2 groups was
statistically significant (P 5 .0003). A similar trend
with the use of a more intensive preparative regimen
was seen in a nonrandomized comparison in patients
with advancedmorphologymyelodysplastic syndromes
(MDS), where the addition of Bu to Cy and 12 Gy TBI
was associated with a lower relapse rate (28% versus
54%) compared to historic controls receiving Cy and
12 Gy TBI alone [11]. Although these studies demon-
strate the benefit for improved tumor control with esca-
lated doses of therapy, they also confirm the clinical
impression that conventional transplant preparative
regimens are currently at the limit of normal organ
tolerance. The higher radiation doses used in the stud-
ies noted before for patients with AML and CMLwere
associated with greater regimen-related toxicities
(RRT) and NRM [7,8]. Similarly, adding Bu to
a regimen of Cy and TBI led to higher NRM [10].
The toxicities that occurred as a result of efforts to
increase the dose of therapy can be attributed to the
nonspecific targeting of the therapeutic agents.
Attempts to develop improved preparative regimens
with increased antitumor effects and less toxicity have
met with only limited success, likely because virtually
all of the various regimens so far are composed of rela-
tively nonspecific agents, such asTBI or high-dose alky-
lating agents. Recent advances offer the potential to
develop substantially improved preparative regimens.
First, to gain the benefit of a GVT effect without the
toxicities associated with a standardHSCT regimen, al-
ternatives to conventional preparative regimens have
been investigated [12–14]. In particular, by carefully
manipulating both pre- and posttransplant immuno-
suppression, complete allogeneic engraftment can be
achieved reliably with very low-dose preparative regi-
mens, a variety of which are shown in Figure 1.Identification of Risk Factors Prior to Allogeneic
HSCT that Predict Relapse: How Important is
Disease Status Prior to Allogeneic HSCT?
Decisions of whether to transplant a patient often
remain a difficult one, and a great deal of consideration
has been given to the identification of factors that will
predict HSCT outcome. Besides cytogenetics, many
patient-, disease-, and treatment-related specific factors
have been recognized that serve as predictors for out-
come such as age, comorbidities, and HLA disparities,
among others. The attractiveness of reduced-intensity
and nonmyeloablative (RIC, NMA) preparative regi-
mens emanates predominantly from their favorable
toxicity profile. The reduced intensity of the employed
conditioning regimens markedly attenuates early mor-
bidity andmortality rates. However, this same attribute
enhances the risk of early relapse because disease
control is almost entirely reliant on the GVT effect,which may require 30 to 60 days to develop. Moreover,
studies assessing risk factors for posttransplant relapse
in patients undergoing RIC allogeneic HSCT have
suggested that failure to achieve a CR prior to HSCT
exerted the greatest adverse impact on the risk of
relapse after transplantation. Additional results from
a second series of non-Hodgkin lymphoma (NHL)
patients treated with RIC allogeneic HSCT identified
response to chemotherapy as the only significant inde-
pendent predictor of relapse, with 75% of patients with
chemotherapy-resistant lymphoma progressing within
1 year after transplant, compared to 25% of patients
with chemotherapy-sensitive disease (P 5 .001). Data
evaluating 64 chronic lymphocytic leukemia (CLL)/
small lymphocytic lymphoma (SLL) patients undergo-
ing RIC allogeneic HSCT confirm these findings and
demonstrate a 2-year relapse rate of 52% in patients
with tumor masses .5 cm in diameter at the time of
transplantation, compared to 14% for patients with
tumors #5 cm (P 5 .009) [15].
Interestingly, little attention has been given so far
to the prognostic impact of minimal residual disease
(MRD), as determined by multiparametric flow cy-
tometry (MFC), at the time of presentation for trans-
plant. MFC, employing a standardized panel of
monoclonal antibodies (mAbs), enables the detection
of small numbers of occult cells that persist during
therapy using technology adaptable by most clinical
laboratories. Determination of MRD levels during
aplasia, early after induction, and/or after consolida-
tion chemotherapy has proven useful to predict relapse
and poor outcome after autologous HSCT and may
help identify patients requiring allogeneic HSCT for
treatment intensification. It is thus conceivable that
these minute populations of persistent cells increase
the likelihood of adverse outcome after HSCT, in
particular, disease relapse. However, it is currently
unclear what role pretransplant MRD, if any, plays
on posttransplant outcome for many patients. To
Figure 2. Estimates of the probability of overall survival and disease-
free survival for AML CR1 patients with negative versus positive MFC
results pre-HSCT (Walter et al., in press).
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MRD for adverse outcome was recently evaluated in
a large cohort of adults with AML in first CR undergo-
ing myeloablative (MA) HSCT. Five-year estimates of
OS as determined by MFC were 26% and 79% for
matched related donor positive MRD1 and matched
related donor negative (MRD2) patients, respectively
(Figure 2) (Walter et al., in press). Two-year estimates
of relapse were 58% and 14%, respectively. After
adjustment for various covariates, patients who were
MRD1 before HSCT remained associated with
a higher risk of relapse (hazard ratio [HR] 5 7.47,
2.67-20.91; P\ .0001) and overall mortality (HR 5
5.16, 2.17-12.27; P\ .0001). These data suggest that
pre-HSCT MRD may be an independent factor for
disease relapse in many patients in first CR after MA
HSCT. A major goal remains to develop preparative
regimens with greater antitumor effects to eliminate
MRD and continued overall less toxicity.Development of Improved Therapeutic
Regimens Prior to HSCT
Conventional chemotherapeutic drugs and external
beam radiation therapy expose normal and neoplastic
cells to identical doses of cytotoxic agents and depend
upon the enhanced sensitivity of rapidly dividing can-
cer cells to achieve preferential killing. In theory, ther-
apeutic efficacy could be markedly enhanced and
toxicity greatly diminished if tumoricidal agents could
be selectively focused on malignant cells, with minimal
exposure of normal cells to cytotoxic agents. Explora-
tion of nontargeted regimens (eg, histone deacetylases
[HDAC] inhibitors, hypomethylating agents) used
prior to HSCT as part of a conditioning regimen war-
rant further attention.Multiple targeted agents, such as
inhibitors of ABL or FLT3 could conceivably be
utilized prior to HSCT: however, a detailed descrip-
tion and rationale of multiple agents will not be
described here because of space constraints. The use
of antibody (Ab)-targeted approaches targeted specifi-
cally to sites of disease, whereas relatively sparing
normal organs have offered significant hope for im-
proved tumor control with minimally increased rates
of toxicity. There are several compelling reasons to
utilize Abs to reduce the risk of disease relapse after
allogeneic HSCT, in particular, for B cell NHL. Abs,
such as the anti-CD20 Ab rituximab, may slow the
growth of residual lymphoma and provide a longer
window for robust graft-versus-lymphoma effects
to develop. In addition to its antitumor effects, Ab-
directed therapies may enhance phagocytosis of apo-
ptotic malignant cells, and promote crosspriming of
cytotoxic T lymphocytes (CTLs). These properties
may be particularly effective in enhancing the GVT
effect after allogeneic HSCT by promoting the devel-
opment of disease-specific donor CTL.Despite the promise of unconjugated Abs, the need
remains to explore alternative immunotherapy strate-
gies and various antigenic targets for therapy. With
the use of radiolabeled mAbs it is possible to deliver
high doses of radiation relatively specifically to bone
marrow (BM), spleen, and other sites of hematologic
malignancies, whereas sparing normal organs. Two
basic strategies have emerged for the use of radioim-
munotherapy (RIT) as part of conditioning regimens.
The first approach emphasizes the efficacy of the ra-
diolabeled Ab by escalating the dose of the RIT and
giving this either with or without high-dose chemo-
therapy. Potential advantages to the escalated RIT
regimen include delivering potentially curative doses
of radiation therapy to all disease sites that may over-
come chemoresistance. Limitations include technical
aspects of dealing with very high doses of radioisotopes
as well as specific dosimetry issues. The second
method utilizes standard NMA radioimmunotherapy
combined with MA chemotherapy. Advantages of
this treatment design primarily include ease of admin-
istration and the potential to escalate therapy above
full chemotherapy-based conditioning regimens,
whereas disadvantages primarily center around the
relatively lose dose of radiation that is delivered to
tumor sites.
A variety of radioimmunoconjugates have been em-
ployed for the treatment of hematologic malignancies.
Most investigators have utilized CD20 or CD22 as
a target for RIT of NHL and either CD33 or CD45
for myelogenous neoplasms. After early dose finding
studies to establish maximum tolerated doses (MTD)
of RIT, select groups have investigated the feasibility
of adding high-dose chemotherapy to the high-dose ra-
diolabeled Ab regimen. For example, it is feasible to
combine 131I-anti-CD45 Ab with standard high-dose
preparative regimens for treatment of AML, ALL,
and MDS [16–18]. An initial study of 131I-anti-CD45
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ALL was performed to determine the biodistribution
of the targeted radiotherapy, as well as estimate the
MTD of radiation delivered by 131I-anti-CD45 Ab
when combined with 120 mg/kg Cy and 12 Gy TBI
[16,17]. Based on the average estimates of radiation-
absorbed doses, treatment at the MTD was projected
to deliver supplemental radiation doses of 24 Gy to
BM and 50 Gy to the spleen. The same regimen was
given in a small Phase II studywhere only 1 of 9 patients
receiving a dose to BM .7 cGy/mCi relapsed, in
contrast to 6 of 9 who relapsed after receiving doses
\7 cGy/mCi to bone marrow (Figure 3) [19]. These
same investigators have also shown that an 131I-anti-
CD45 Ab can be combined with standard high-dose
preparative regimens for treatment of younger patients
with leukemia, and that in the specific setting of AML
in first CR a regimen combining radiolabeled Ab with
standard Bu and Cy has given encouraging results
[18]. More recently it has been shown that high doses
of targeted radiotherapy can be safely combined with
anRIC preparative regimen in older relapsed or refrac-
tory patients with myelogenous malignancies [20]. In
this study, designed to estimate the MTD, the esti-
mates of survival and relapse were highly encouraging
for this extremely high-risk patient population where
the standard RIC regimens are likely not active enough
in patients with relapsed disease. Treatment with this
approach produced a CR in all patients, and all had
100% donor-derived CD31 and CD331 cells in the
blood by day 28 after the transplant. The estimated
probability of recurrent malignancy at 1 year is 40%,
and the 1-year survival estimate is 41%.The1-year sur-
vival estimate was 48% (95% CI, 26%-67%) among
the patients who received the MTD (Figure 4).Figure 3. Probability of relapse for advanced AML patients who re-
ceived 131I-BC8 Ab combined with CY/TBI. Thick solid line 5 dose to
BM .7 cGy/mCi; thick dashed line 5 dose to BM\7 cGy/mCi [19].Although the estimated probability of relapse at 1
year remains high, these results appear to be encourag-
ing considering that 86% of the patients in the study
had active AMLorMDSwith.5%blasts at the begin-
ning of the conditioning regimen, in contrast to results
from studies using a fludarabine (Flu)/TBI-based RIC
alonewhere aGVTeffect appeared to bemost effective
in patients with a low burden ofmalignant cells [21,22].Unanswered Clinical Challenges and Program
Initiative
Despite current advances in allogeneic HSCT, the
central cause of failure in the vast majority of cases is
relapse of disease. Thus, new strategies are needed to
improve outcomes associated with allogeneic HSCT.
Achieving this goal depends on the development of
more effective and safer modalities for maximizing
the antitumor potential of allogeneic HSCT. To
achieve optimal elimination of tumor cells, a number
of challenges remain. Outlined here are nontargeted
and targeted approaches to improving the condition-
ing regimens that have the potential to increase the
therapeutic success of allogeneic HSCT. Clinical trials
focusing on these approaches should be considered.
Drug therapy postallogeneic transplant to
prevent relapse
The role of chemotherapy following HSCT has
been poorly studied. Most of these approaches have
been limited to ABL kinase inhibitors in patients with
Philadelphia chromosome positive (Ph1) leukemias.
However, other strategies including the use of interleu-
kins, mAbs, immunomodulatory agents (thalidomide
and lenalidomide), DNA methyltransferase inhibitors,
and histone deacetylase inhibitors are currently being
explored. The goal of these approaches is to treatFigure 4. Estimates of the probability of OS, DFS, TRM, and relapse
among patients treated at the MTD of 24 Gy of radiation delivered to
the liver by the 131I-BC8 Ab, followed by TBI/Flu [19].
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ing the impediment of donor cell engraftment. The
administration of chemotherapy after HSCT remains
an open area for exploration.
Ph1 leukemias (CML and ALL)
The treatment of patients with Ph1 leukemias has
undergone a marked change over the past several years
[23]. The current approach for patients with a Ph1 ab-
normality is to administer a tyrosine kinase inhibitor
(TKI), such as imatinib [24,25]. For those patients
with chronic phase CML, the current standard is
imatinib at 400 mg per day. Given the recent data
from the IRIS trial [23,26] as well as from a German
randomized study [27], imatinib remains the standard
of care for patients with chronic phase CML. Given
the high response rates to the second-generation
TKIs, dasatinib and nilotinib, most patients who fail
imatinib will receive a trial of 1 or both of these agents
prior to HSCT [27,28]. SCT, therefore, has been
relegated to patients whose disease fails to respond
or progress while on a second-generation TKI, and
therefore, most patients who have received at least 1
second-generation TKI. In the case of chronic phase
CML, the use of TKI may not eradicate the resistant
clone.
Mechanisms of resistance in patients with CML
include tyrosine kinase domain (TKD) mutations as
well as many other host and disease markers [29]. In
those patients who have an identified TKD mutation
that renders the disease resistant to the available
TKIs, for example, T315I, the role of TKI therapy
post-SCT is unclear [30,31]. In patients who fail
TKI therapy prior to undergoing an HSCT, the
additional administration of TKIs post-HSCT is
unlikely to provide significant benefit.
The role of TKI therapy following HSCT in other
Ph1 leukemias is actively being explored and is more
sensible. The standard of care for patients with Ph1
ALL is allogeneic HSCT in first CR, assuming that
the patient has an available donor and is of reasonable
health. For these patients, a course of imatinib or dasa-
tinib is typically administered prior to HSCT [25].
The use of TKI therapy post-HSCT is currently being
explored in several studies including a trial being con-
ducted by Cancer and Leukemia Group B (CALGB
10001; NCT00039377) [32]. Similarly, allogeneic
HSCT remains a standard approach for patients with
myeloid or lymphoid blast crisis (BP-CML) as well
as accelerated phase CML (AP-CML). Two groups
of patients exist: those patients who present with de
novo disease, and those patients who transform from
underlying CP-CML. For the newly diagnosed pa-
tient, exposure to TKI therapy prior to HSCT is often
limited, and therefore the use of TKI therapy post-
HSCT is extremely reasonable. For patients withCP-CML who transform or progress while on TKI
therapy, the use of TKI therapy posttransplant is less
likely to be efficacious owing largely to the presence
of TKD mutations.
The current TKIs that are currently available
(imatinib, dasatinib, and nilotinib) are all resistant to
the T315I mutation. Therefore, patients who contain
a T315Imutation will not benefit frommoreTKI ther-
apy. Several agents are under development to address
this problem. MK-0457, an aurora kinase inhibitor,
blocked autophosphorylation of the T315I BCR-ABL
mutant in preclinical assays. This agent also showed
antiproliferative effects against patient-derived CML
cells harboring this mutation [33–35]. Early phase I/II
data demonstrated responses in 3 of 3 patients with
the T315I mutation [36]. However, as of this writing,
clinical trials with MK-0457 had been suspended
because of toxicity concerns.
Several other small-molecule TKIs have demon-
strated activity against the T315I mutation. The au-
rora kinase inhibitor PHA-739358 has shown activity
among patients with the T315I mutation in early-
stage clinical trials. The TKIs AP-24534 and XL228
have shown promising results both in cell culture and
in mice bearing xenograft tumors expressing the
T315I BCR-ABL mutant. A phase I randomized,
opened-label trial of XL228 has recently been initiated
in patients with Ph1 leukemia, and clinical trials are
planned for AP-24534 in patients with drug-resistant
CML. Another small molecule inhibitor, WP1130,
has been shown to decrease native BCR-ABL and
T315I mutant protein levels in CML cells [37].
CLL/SLL
CLL/SLLhas also undergone a paradigm shift over
the last decade [38,39].Nucleoside analog therapy,most
commonly with Flu-based regimens, is now the stan-
dard of care. In addition, given the high expression of
CD20, most patients will receive rituximab. The addi-
tion of rituximab to standard nucleoside analog therapy
has improved the response rates as well as disease-free
survival (DFS) [40]. Although it is difficult to assess its
specific effect on OS, the majority of patients are cur-
rently receiving rituximab therapy, and therefore ritux-
imab therapy post-HSCT is unlikely to be of benefit.
However, additionalmAbs are currentlybeing explored.
Lumiliximab is an mAb directed against CD23.
This is currently being tested in a large, randomized
phase II registration trial with Flu, Cy, and rituxan
with or without lumiliximab. Given the absence of
any complete or partial responses as a single agent,
its use as a single agent in the maintenance period
post-SCT would be unlikely to derive benefit.
There are CD20 epitopes to which rituximab does
not bind. For example, ofatumumab is another anti-
CD20 mAb that interacts with a distinct small loop
Biol Blood Marrow Transplant 16:1037-1069, 2010 1043NCI First International Workshop on Prevention/Treatment
of Relapse after AlloHCTepitope on the CD20molecule [41]. Studies have dem-
onstrated impressive clinical response rates in the 20%
to 60% range. Therefore, contrary to the fact that
most patients with CLL/SLL have been previously
treated with rituximab, very few patients would have
been treated with ofatumumab, and therefore, ofatu-
mumab may be a therapeutic option for patients with
CLL/SLL following the HSCT period.
Other approaches for the treatment of CLL/SLL
post-HSCT include the CAL101, a small molecule in-
hibitor of the p110-delta PI3 kinase (PI3K) [42]. This
is currently undergoing exploration in a phase I multi-
center trial. In addition, 2BCL2 inhibitors are currently
being explored in CLL/SLL. This includes the
ABT263 as well as obatoclax (GX015-070) [43–45].
The difficult problem with ABT263 is dose-limiting
thrombocytopenia, which is related to BCL-XL inhibi-
tion. Another mAb is alemtuzumab (Campath), which
is directed against CD52. Linn and colleagues [46]
reported the experience from the CALGB, in which
case there were significant upfront deaths in patients
treated with alemtuzumab after Flu and rituximab-
based chemotherapy in hopes of treatingMRD.Unfor-
tunately, alemtuzumab showed significant toxicity
when used in a maintenance therapy. Lenalidomide is
another agent with high single-agent activity in Flu-
refractory patients with CLL/SLL. Its use as posttrans-
plant therapy may be of benefit [47,48].
Acute myeloid leukemia/myelodysplastic
syndromes
Therapy following HSCT for patients with AML
has been poorly studied. The use of immune-
modulating agents such as interleukin 2 (IL-2) was in-
vestigated given the success of adaptive immunotherapy
(ie, DLI) in salvaging patients following allogeneic
transplant. Recombinant IL-2 has activity in renal cell
carcinoma andmalignantmelanoma can activateT cells
as well as natural killer (NK) cells to generate activated
cytotoxic effectors such as lymphokine activated killer
(LAK) cells. These cells are able to lyse tumor targets.
The administration of rIL-2was tested in a patients
with AML following high-dose cytarabine (ara-C) as
consolidation therapy [49]. This was a nonrandomized
study, and was reasonably tolerated. rIL2 was associ-
ated with a fivefold increase in circulatingNK lympho-
cyte levels and a threefold increase in circulating CD4
and CD8 T-lymphocyte levels. The CALGB evalu-
ated the use of rIL-2 immunotherapy for MRD in
a phase III trial in patients with AML in first CR after
completing all planned chemotherapy [50]. Postremis-
sion therapy was based on cytogenetic risk factors:
patients with core binding factor (CBF) AML received
3 courses of high-dose ara-C (HiDAC), whereas all
others were assigned to receive a 2-step autologous
HSCT regimen [51]. Although on an attempt-to-
treat basis, there was no significant improvement indisease-free (56% versus 45%, P 5 .11) or OS (68%
versus 61%, P 5 .09). The problem with this study
was that few patients received their full scheduled
dose rIL-2 therapy, therefore making interpretation
of the analysis somewhat complicated. Similar studies
were also ineffective in patients over the age of 60 years
with AML [52].
The use of hypomethylating agents (eg, 5-
azacitidine) inpatientswithMDShasbecomea standard
approach, specifically in those patients with high-risk
disease. Recent data demonstrate that patients with
high-risk MDS treated with hypomethylating agents
have a survival benefit as compared to best supportive
care (24 months versus 15 months) [53]. 5-Azacitidine
and decitabine share similar structures and presumably
similar mechanisms of action. They seem to target
DNA methyltransferase activity in leukemic cells.
Decitabine is a deoxyribonucleic sugar base as opposed
to 5-azacitidine, which is a ribonucleic acid sugar base.
Toxicity profiles of both agents have been recently
reported, and both agents are approved in the United
States for patients with MDS as well as early AML
(20-30% myeloblasts).
In early clinical trials, the most common side effect
was prolonged myelosuppression. However, in gen-
eral, these agents have been well tolerated. At high
doses, both agents have significant cytotoxic activity.
When used a low doses, however, they seem to con-
tribute more as a differentiating agent owing predom-
inantly through DNA methyltransferase inhibition.
Initial studies from the CALGB using low-dose
azacitadine at 75 mg/m2 per day subcutaneously for
7 days of each month resulted in a longer median
time to AML progression (P5 .0034) and a decreased
probability of leukemic transformation (P 5 .003)
compared to best supportive care [54]. The optimal
dose of decitabine is unclear. In the initial studies,
decitabine was administered at a dose of 15 mg/m2
over 3 hours every 8 hours for 9 doses [23]. The
M.D. Anderson Cancer Center employed a different
dosing schedule using 20 mg/m2 per day for 5 days
a week with repeat cycles every 4 to 5 weeks [55].
The addition of hypomethylating agents, either
5-azacitadine or decitabine, is currently being studied
in patients with both MDS and AML following
completion of chemotherapy [56,57]. The CALGB is
administering decitabine as a maintenance therapy in
patients with AML in first CR who have recovered
from an autologous HSCT (NCT00416598).
One of themost important histone posttranslational
modifications is acetylation of lysine residues of histone
subunit H3. Acetylation at lysine residues can result in
transcriptional activation of the DNA associated with
the acetylated histone. In contrast, acetyl groups are
removed by HDACs, of which there are 4 classes with
at least 11 enzyme members, with both class-specific
and enzyme-specific biologic effects [53,58–60]. A
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chemical structural class are currently enrolling
patients with hematologicmalignancies [59]. Entinostat
(SNDX-275/MS-275) and MGCD0103 selectively in-
hibit only class I HDACs (ie, HDACs 1, 2, 3, and 8),
whereas other agents, such as panobinostat (NVP-
LBH589), inhibitHDACsmorebroadly [60]. In clinical
trials, mostHDAC inhibitors have been associated with
severe fatigue and gastrointestinal adverse events, such
as nausea and diarrhea.
Multiple myeloma (MM)
Thalidomide exerts its effect on myeloma cells by
the enhancement of T cell and NK cell-mediated im-
munologic response, disruption of adhesion between
MM cells and surrounding stromal cells, and induction
of caspase-8-mediated apoptosis [61]. Thalidomide-
based therapies have proved to be effective in patients
with relapsed and refractory MM, as well as in those
with newly diagnosed disease [62,63]. Along with its
conventional role, thalidomide has been evaluated as
maintenance therapy following autologous HSCT
[64]. There are reasons that this approach should be ad-
vantageous. First, a substantial number ofMMpatients
who undergo autologous HSCT exhibit evidence of
persistent disease following autologous HSCT. More-
over, even patients who achieve a CR ultimately
relapse, demonstrating that the MM clone persists
despite aggressive cytotoxic chemotherapy.
Several studies have provided evidence in support
of maintenance therapy. A randomized phase II study
by Stewart and colleagues [65] demonstrated the effi-
cacy of thalidomide as maintenance therapy and estab-
lished a feasible dosing schedule. Attal and colleagues
[66] subsequently conducted a randomized study in
newly diagnosed 597 patients, who were randomiza-
tion to either no maintenance, pamidronate alone, or
pamidronate and thalidomide following postautolo-
gous HSCT. Thalidomide-containing maintenance
therapy was associated with a significant improvement
in both 3-year event-free survival (EFS) and 4-yearOS.
The greatest benefit was seen in patients who achieved
less than a very good partial remission (VGPR) and
with favorable cytogenetics. Barlogie and colleagues
[51] conducted a study in 668 newly diagnosed patients
with MM who received the total therapy with or with-
out thalidomide from the initiation of therapy until
disease progression. The addition of thalidomide
resulted in a significant improvement in the CR rate
and 5-year EFS, although there was no improvement
in OS.
A shorter postrelapse median OS time was noted in
patients who received thalidomide. Ongoing thalido-
mide treatment could contribute to disease resistance,
thus decreasing the likelihood of successful retreatment
at the time of relapse. This concept was supported by
the preliminary analysis of theMedical ResearchCoun-cil’s Myeloma IX study, in which 820 newly diagnosed
patients were randomization to either thalidomide
maintenance or nomaintenance. Interestingly, thalido-
mide was not associated with a significant benefit in
progression-free survival (PFS) for thegroup as awhole,
but a significant improvement was seen in patients who
failed to achieve at least a VGPR with intensive induc-
tion therapy. Current approaches are administering
thalidomide following a reduced-intensity allogeneic
HSCT platform (NCT00777998). In addition, lenali-
domide and bortezomib, 2 extremely active drugs for
the treatment of both newly diagnosed and relapsed/
refractory patients with MM are currently being
studied as maintenance therapy following autologous
HSCT as well as RIC allogeneic HSCT approaches
(NCT00847639; NCT00778752; NCT00504634).
Unanswered Clinical Challenges and Program
Initiative in Drug Therapy
To improve allogeneic HSCT outcomes, it will be
important to better define populations at the greatest
risk of relapse. Differences based on disease status at
the time of transplant will likely have an impact on
the kinetics of relapse and therefore define the time
interval available for chemotherapy intervention.
Monitoring of MRD, which is currently available in
only certain diseases, may serve as a powerful tool to
identify appropriate patients for drug therapy post-
HSCT. Future studies will need to define dose as well
as timing of drug therapy post-HSCT. It may be
reasonable to explore the safety of administering drug
therapy while patients are still on immune suppression.GRAFT ENGINEERING
Hematopoietic stem cell grafts contain immune
cells that contribute to engraftment, immune reconsti-
tution, a GVT effect and graft-versus-host disease
(GVHD). The administration of immunosuppressive
drugs or antilymphocyte antibodies is necessary to pre-
vent GVHD caused by alloreactive donor T cells that
are present in unmanipulated HSC grafts. Unfortu-
nately, immunosuppressive drugs also suppress the
function of T cells that provide protection from patho-
gens and promote a GVT effect. Thus, transplantation
withunmanipulated stemcell grafts poses a conundrum
for employing cellular immunotherapy to selectively
target malignant cells and prevent or reduce relapse.
GVHD and/or the drugs used to prevent or treat
GVHD may also interfere with the absorption, phar-
macokinetics, and toxicity of drug therapies that might
be administered after transplant to target residual
malignancy.
The notion of manipulating or engineering hema-
topoietic stem cell grafts tomitigate GVHD and retain
or augment the GVT effect has long held conceptual
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of Relapse after AlloHCTappeal, but logistics and technical complexity have
limited clinical evaluation, and a method to reproduc-
ibly avoid GVHD and retain GVT activity remains
elusive. Here, strategies that are being investigated
for the engineering of hematopoietic stem cell grafts
and issues for future investigation will be discussed.
Removal of T Cells from HSC Grafts to Prevent
GVHD
Complete T cell depletion (TCD)
The complete removal of T cells from stem cell
grafts can be accomplished using clinically approved de-
vices for positive selection of CD341 hematopoietic
progenitors, and is effective for preventingGVHDafter
MA conditioning and HLA matched or haploidentical
HSCT without the need for post grafting immunosup-
pression [67,68]. An alternative method that depletes T
cells from the graft is to add the mAb alemtuzumab to
the stem cell product and/or administer it to the
patient during conditioning [69]. In initial studies,
TCD was associated with an increased risk of graft
failure and leukemia relapse, and with delayed reconsti-
tution of pathogen-specific immunity. A study in HLA
identical HSCT recipients at Memorial Sloan-
Kettering Cancer Center achieved engraftment with
a low incidence (\10%) of both acute and chronic
GVHD (aGVHD, cGVHD) using Flu, thiotepa, and
TBI for conditioning and a CD34 selected HSC graft
[68]. CD4 T cell recovery was improved compared
with prior studies in which antithymocyte globulin
(ATG) was used in the conditioning regimen, although
absolute CD4 counts remained\200 cells/mL for .7
months in a large fraction of patients. Relapse and
survival were comparable to results reported by other
centers in which patients were transplanted with
unmodified grafts [68]. A multicenter phase 2 trial of
complete TCD in AML in first or second CR has
been completed in the United States, and formal publi-
cation of the data is expected soon. The absence of
GVHD and pharmacologic immunosuppression, and
the elevation of IL-15 and IL-7 because of lymphopenia
suggest thatTCDmayprovide aplatformfor targetedT
cell therapies to prevent or treat relapse.However, strat-
egies to resolve the immunodeficiency that occurs after
complete TCD such as promoting the production of
naı¨ve T cells by the recipient thymus will be necessary
to improve outcome [70].
Selective depletion of alloreactive T cells
Itwouldbe ideal if alloreactiveTcells couldbe selec-
tively removed from stem cell grafts tomitigateGVHD.
Such an approach could preserve immunity to patho-
gens, hasten immune reconstitution, and improve the
prospects for post transplant adoptive T cell therapy or
vaccination to augment the GVT effect. A theoretical
advantage of selective depletion of alloreactive T cellsis that aGVTeffectmight still arise de novo fromTcells
in the graft that recognize nonpolymorphic leukemia
antigens such as Wilms’ tumor gene (WT-1) and pro-
teinase 3. Methods for removal of alloreactive T cells
typically rely on coincubating donor lymphocytes with
allogeneic recipient stimulator cells, and then depleting
the alloreactive subset based by linking an antibody
specific for a cell surface activation marker to an immu-
notoxin or an immunomagnetic bead. Several activation
markers have been evaluated for this purpose including
CD25, CD69, CD137, and CD134 [71–73] . A key
issue for these strategies is the choice of recipient
APC to activate donor T cells in vitro, because it is
uncertain whether alloantigens that are targets for
GVHD are expressed in all recipient cell types.
The clinical translation of selective depletion of
alloreactive T cells has been challenging, in part
because of the need for specialized reagents and for
in vitro manipulation of the stem cell products. Deple-
tion of T cells that express CD25 after activation with
recipient cells has been evaluated clinically in both
haploidentical and HLA matched transplants, and
may confer a reduced incidence of GVHD [74,75].
Insufficient data is available to determine if the GVT
effect of the graft is compromised, although it is
logical to assume that it will be to some degree.
An alternative to depleting alloreactiveT cells from
the stem cell graft is to administer a large dose of Cy
early after infusion of a T cell-replete HSC graft to
eliminate alloreactive T cells that have been induced
to proliferate by antigen engagement. Although this
approach does not completely eliminate the need for
immunosuppressive drugs, it has reduced the incidence
of severe GVHD after T cell-replete haploidentical
and HLA identical HSCT [76].Depletion of naı¨ve T cells
The identification of phenotypic and functional
subsets of T cells including Tregs, antigen inexperi-
enced naı¨ve T cells (TN), and antigen experienced
memory T cells (TM), has provided opportunities for
manipulation of allogeneic grafts that might reduce
GVHDwithout the severe T cell deficiency associated
with complete TCD. Studies in murine models have
revealed that GVHD develops as a consequence of tis-
sue injury, activation and proliferation of alloreactive
donor T cells in lymphoid organs, and the migration
of these T cells to tissue sites. In mice, the induction
of GVHD is attenuated by CD41 CD251 Tregs in
lymph nodes early after HSCT and the transfer of
CD41 CD251Treg is being investigated for reducing
GVHD in humans [77]. An alternative approach that is
effective for GVHD prevention in murine models and
preserves transfer of immunity to pathogens is based
on the removal of TN cells [78]. The intent in these
murine studies was to deplete TN, but the cell selection
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subset of TM, which express CD62L. Recent experi-
ments in which purified TN, TCM, or TEM were trans-
planted with TCD bone marrow in a murine model
of GVHD, showed that TN caused severe GVHD,
TCM caused mild GVHD, and TEM did not cause
GVHD [79].
HumanTN and TM can also be distinguished based
on phenotype: TN are CD45RA
1, CD62L1 and CCR-
71, whereas TM are CD45RO
1 and either CD62L1
CCR-71 (TCM) or CD62L
2 (TEM) [80]. Sequencing
of T cell antigen receptor (TCR) genes from purified
human TN and TM to estimate the diversity of ab
TCRs shows that theTN repertoire contains the greater
overall TCR diversity than the TM subset [81,82].
Functional studies show that a major component of
all CD41 and CD81 TM are specific for persistent
viruses such as cytomegalovirus (CMV), Epstein-Barr
virus (EBV), herpes simplex virus (HSV), and varicellar
zoster virus (VZV). Although virus-specific T cells can
crossreact with alloantigens, this typically represents
recognitionof allogeneicMHCrather thanminorHan-
tigens and appears to be rare [83,84].Direct evidence for
differences in the alloreactive T cell repertoire between
CD81 TN and TM subsets has been shown using
limiting dilution analysis of rigorously purified T cells
from nonparous, untransfused HLA identical sibling
pairs [85]. A multicenter phase 2 trial in which TN cells
will be depleted from HSC grafts for prevention of
GVHD in HLA identical siblings has been initiated,
and if effective may provide a platform for adoptive T
cell therapy with leukemia-reactive T cells to augment
the GVT effect without GVHD.Addition of Cells to Enhance GVL Effect without
GVHD
A variety of immune effector cells and target
molecules on leukemic cells have been identified and
linked to an effective GVL response [85]. Studies to
evaluate the antitumor activity of defined effector cells
in patients who have relapsed after HSCT have been
initiated. If safety is established in these studies, it
may be reasonable in the future to consider supple-
menting the stem cell graft with such tumor-reactive
cells to prevent relapse from occurring, or to select
donors based on genotyping that would predict that
alloreactive NK cells or T cells capable of promoting
GVT without GVHD will be contained in the graft.
NK cells
Because the original description of the capacity of
NK cells to lyse certain tumor cells in vitro without
priming, a wealth of information has emerged on NK
cell differentiation and how input signals from
receptors expressed on these cells regulate their activa-
tion [86]. A feature ofNKcells is the expression of killerinhibitory receptors (KIR) that recognize groups of
class I HLA alleles, and inhibit NK cytotoxicity. A sub-
set of haploidenticalHSCT recipientsmay lack a class I
MHC allele needed to interact with KIR on donor NK
cells in the graft, and in such ‘‘KIR-ligand’’mismatched
haploidentical settings, inwhich theHSCgraft is rigor-
ously T cell depleted, an accentuated GVL effect
mediated by alloreactive NK cells has been observed
for AML without GVHD [67,87]. Subsequent studies
attempting to document beneficial effects of NK cell
alloreactivity in other HSCT settings have suggested
that factors including stem cell dose, degree of T cell
depletion, donor source, and GVHD prophylaxis
determine the potency of the antileukemic effect
mediated by donor NK cells [87]. Efforts to adoptively
transfer NK cells to treat leukemia relapse both after
HSCT and in the non transplant setting have been
initiated to determine the safety of this approach and
establish principles for NK cell therapy [88].
T cells
Several methods of increasing the number of T
cells that could potentially mediate a selective GVL
effect in the patient without causing GVHD are being
investigated including the adoptive transfer of T cells
specific forminorH antigens that are restricted in their
expression to cells in the hematopoietic lineage, or
T cells specific for leukemia associated antigens such
as proteinase 3 or WT-1. Additionally, any donor T
cell can be engineered by gene transfer to express
a T cell receptor or chimeric antigen receptor that
targets a molecule on leukemic cells [89,90]. These
approaches involve significant technical complexity
and are discussed later in this review, but offer the
potential to provide an antileukemic effect without
GVHD. The ability of transferred T cells to function
optimally in vivo is likely to depend on developing
transplant regimens that do not require prolonged
pharmacologic immunosuppression to prevent or
treat GVHD. If the safety and efficacy of T cell
therapy is established, it may be more efficient to
supplement the HSC graft with antileukemic T cells
or to administer the cells soon after transplant.
An alternative to increasing the GVT effect of the
HSC graft that might be suitable for HLA identical
family member transplants is to vaccinate the donor
to increase the frequency of T cells in the donor (and
theHSC graft) that are specific for leukemia associated
determinants. In the case of minor H antigens, this
would require genotyping the donor and recipient to
define appropriate targets for vaccination, and may
carry some risk to the donor. Vaccination to induce
T cell responses to self-antigens such as WT-1 or
proteinase-3 has been evaluated in patients with leuke-
mia and yielded provocative results [91–93], but safety
concerns make this impractical for donors. Vaccines
might also be given to the recipient after HSCT and
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capable of responding to vaccination by the recipient
thymus were increased [94]. A potential impediment
is that the best strategies for inducing T cell responses
in humans by vaccination have not been established.
Genetic Modification of the Graft to Regulate
Donor T Cell Survival
The insertion of an inducible suicide gene in donor
T cells in theHSCgraft offers the ability to eliminateT
cells that cause GVHD if necessary, and potentially
retainGVTeffects that aremediated prior to activation
of T cell death. The most extensively studied suicide
gene is the herpes simplex virus thymidine kinase
(HSV-TK) gene, which encodes an enzyme that
phosphorylates the drug ganciclovir into moieties
that inhibit DNA elongation and kill dividing cells.
Several phase 1 and 2 studies in humans have examined
the immediate or delayed transfer of donor T cells
modified to express HSV-TK [95,96]. These studies
have demonstrated feasibility and safety, and affirmed
the principle that ganciclovir administration can
eliminate HSV-TK-modified T cells and control
GVHD. It is less clear how effectively GVL responses
are maintained, and this may depend on how long
donor T cells persist in vivo before elimination. The
culture conditions used for gene transfer, the potential
for immune responses to HSV-TK to develop, and al-
terations in the TK gene that results in a nonfunctional
protein have been identified as limitations of this
approach [97,98].
These limitations have encouraged the develop-
ment of alternative conditional suicide genes. An ideal
suicide gene would be nontoxic until activated, derived
from or highly homologous to a human protein to
reduce recognition by host immunity, and efficiently
trigger cell death when activated. Chimeric FKBP-
Fas or FKBP-caspase molecules that can be dimerized
by binding of nontoxic chemical dimerizer to the
FKBP moieties have shown promise [99]. Although
both Fas and caspase are effective, the caspase based
vectors confer greater sensitivity to dimerizer drug
[100]. Because these chimeric molecules are human
proteins, the chances of an immune response to the
transgene product are less. In vivo experiments in
nonhuman primates have demonstrated the safety
and efficacy of inducing cell suicide in adoptively
transferred T cells that expressed an Fas-based suicide
gene [101], and a clinical trial of a caspase construct is
in progress.
Unanswered Clinical Challenges and Program
Initiative in Graft Engineering
Although conceptually appealing, the use of graft
engineering to achieve segregation of GVT activity
from GVHD remains speculative. This reflects boththe technical complexity of manipulating the cellular
content of stem cell grafts and our incomplete under-
standing of the role of individual cells in mediating
beneficial and deleterious consequences in the recipi-
ent. Several issues must be addressed to move the field
forward. The most immediate issue is to determine the
best platform/graft composition to enable posttrans-
plant cellular or pharmacologic therapy to prevent or
treat relapse. Additional research is needed to define
the role of individual innate and adaptive effector cells
in mediating a GVT effect and understanding how
these cells interact. Finally, the role of individual cell
subsets in GVHD and GVT is likely to differ depend-
ing on the HLA disparity, minor H antigen disparity,
other genetic polymorphisms in the donor and recipi-
ent that affect the immune response, and the type of
conditioning the patient receives, and these factors
are likely to influence how HSC grafts might be mod-
ified to achieve the best patient outcome.DCS IN TRANSPLANTATION AND IMMUNE-
BASED THERAPIES
DCs comprise a complex system of BM-derived
leukocytes that are critical to the onset of both innate
and adaptive immunity [102–104]. The anatomic
distribution of DCs in blood, tissue, and lymphoid
organs segregates with specific subsets and functions.
In this way, DCs control lymphocyte priming and
determine the type of immune response. We will
therefore focus here on the afferent sensitization of
cellular immunity by DCs, in the context of strategies
to prevent or treat posttransplant relapse. We will
also explore how desired GVT effects might be
distinguished from GVHD at the level of antigen
presentation.
Hematopoietic Development of Dendritic Cells
DCs differentiate along 2 main pathways from cy-
cling CD341 hematopoietic progenitor cells (HPCs).
One pathway leads to plasmacytoidDCs (pDCs), which
respond particularly to viral infections and secrete enor-
mous amounts of type I interferons that can activateNK
cells and NKT cells. These, in turn, secrete inflamma-
tory cytokines that activate the myeloid or conventional
DC progeny of the other main differentiation pathway
from CD341 HPCs. These myeloid or conventional
DCs comprise Langerhans cells (LCs), which populate
all stratified epithelia, including skin and mucosal
surfaces, and dermal-interstitial DCs (DDC-IDCs),
which populate their eponymous tissues.
In addition, non-dividing DC precursors circulate
in blood, as do trace populations of already differenti-
ated DCs. The nondividing precursors of plasmacytoid
DCs are again highly responsive to viral products
for differentiation and activation. Blood monocyte
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derived DCs (moDCs), show the greatest plasticity in
terms of differentiation in response to various cyto-
kines, which determine the specific types of immune
responses, for example, inflammatory, autoimmune,
or allergic responses. The exact counterparts of these
moDCs have not been clearly identified in vivo, so
they are still defined by their characteristics after cyto-
kine generation in vitro. Nevertheless, circulating
blood monocytes remain the most readily accessible
DC precursors and are therefore most often used by
translational investigators for DC-based vaccines in
clinical trials. This is regardless of recent evidence
that LCs generated in vitro with recombinant cytokines
from mobilized CD341 HPCs are more potent than
moDCs in stimulating antigen-specific cytotoxic T
lymphocytes (CTLs), despite the lack of IL12p70
secreted by LCs [105–108]. Mature moDCs secrete
ample IL12p70, which instead supports activation of
resting NK cells [109].
Tissue distribution and the state of DC
maturation and activation determine the type of
lymphocyte response
Under non-inflammatory steady-state conditions,
immature DCs are most adept at antigen uptake and
processing, and are hence distributed throughout the
periphery at sites most likely to encounter antigen.
DCs are also a major component of lymphoid tissues
in the steady state where they have migrated without
the same cytokine transcriptional profile as occurs
under conditions of inflammation [110]. DCs in
these noninflamed conditions express C-type lectin
receptors, which bind carbohydrate moieties of glyco-
protein self-antigens and harmless environmental anti-
gens for processing and presentation on MHC
molecules to induce andmaintain tolerance [110–112].
DCs require some form of terminal maturation
and activation stimulus to become fully immunogenic,
and this is a pivotal event in the control of innate and
adaptive immunity.Microbial products provide a phys-
iologic activation stimulus via Toll-like receptors
(TLRs) on both plasmacytoid and conventional DCs.
Such products are plentiful in the early peritransplant
period and certainly underlie the cytokine storm that
contributes to DC activation and the onset of
GVHD [113]. Activated T cells expressing CD40L
(CD154) or multimeric recombinant CD40L can
alsomatureDCs. Ligand binding of TLRs upregulates
cytokine secretion, costimulatory molecules, the mat-
uration marker CD83, and CCR7, which supports
DCmigration to T cell areas of draining lymph nodes.
Early activated DCs stimulate and recruit NK and
NK T cells, which then secrete IFN-gamma and other
inflammatory cytokines that support the bystander
activation of other DCs. The ensuing adaptive immune
response generates CD41 and CD81 T cells, as wellas other effectors like Th17 and suppressor Tregs
[104,114,115]. Appropriate stimulation of TLRs on
DCs by their respective ligands can thus initiate the
entire spectrum of innate, and in turn, acquired
immunity, as well as regulatory responses that probably
serve to counter an otherwise unchecked immune
response. Not all TLR agonists yield the same
activation profile in mature DCs. A combination of
inflammatory cytokines that includes IL-1-beta, tumor
necrosis factor (TNF)-alpha, IL-6, and PGE2 is often
used tomatureDCs for study in vitro and for use in clin-
ical vaccine trials [116].Thismimicsmostof the sequelae
of physiologic TLR ligand binding.
Antigen uptake, processing, and presentation:
DCs as crosspresenters
DCs have the same machinery as other antigen-
presenting cells (APCs) to process and present antigen
on class I and II MHC, although they express an enor-
mous surplus of MHC molecules allowing simulta-
neous presentation of many antigenic peptides. DCs
are specially endowed, however, with the ability to
crosspresent exogenous antigens on the DCs’ own
class I, as well as the usual class II, MHC molecules
to autologous T cells. This occurs regardless of the
MHC alleles expressed by the antigen source [117–
119]. Cytokine-induced, CD341 HPC-derived LCs
are much less phagocytic than the more commonly
studied and used moDCs, yet LCs elicit more potent
T cell responses by crosspresentation [106]. Hence,
LCs must process much more phagocytosed antigen
for MHC-restricted presentation than do moDCs,
which instead sequester and degrade much of what
they take in.
Investigators have also emphasized distinctions be-
tween apoptotic and necrotic cell death as a source of
crosspresented antigens. The key operative, however,
is whether antigen remains intact or denatured during
apoptosis or necrosis, as well as whether there are any
additional danger signals. These are the greater deter-
minants of effective crosspresentation and a tolerant or
immune outcome [120].
Questions
How might we separate GVHD from GVTat the
level of antigen presentation?
To begin to address this question, one must con-
ceptually distinguish the afferent sensitization of
GVH and GVT interactions by distinct DC subtypes
from the effector responses mediated by responding
lymphocytes. Monocyte precursors can circulate and
survey tissues, rapidly differentiate into potent moDCs
in response to ambient cytokines in the microenviron-
ment, and then migrate to draining lymph nodes to
sensitize circulating T cells. In some ways, monocytes
provide ‘‘DCs on demand.’’ MoDCs are therefore
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sponses under conditions of severe inflammation.
Such inflammation may exist in the early posttrans-
plant period, creating the ‘‘perfect (cytokine) storm’’
to support moDC initiation of GVH [113]. T cells
activated in this setting then have greater access into
inflamed tissues where they can target resident popula-
tions of DCs like LCs and DDC-IDCs that normally
have slower turnover [121,122]. When inflammation
that promotes LC or DDC/IDC migration to
draining lymph nodes exceeds the capacity of local
precursors to replenish these populations, BM
progenitors move into the tissues to fill that void
[121,122]. In allogeneic HSCT, then, donor-derived
DC subtypes can in this way replace long-lived host
LCs and DDC-IDCs in the peripheral tissues, some-
times long after blood myeloid donor chimerism has
been established.
Interestingly, monocyte precursors and their
moDC progeny express CD52, targeted by alemtuzu-
mab [123]. One might hypothesize then that the use of
alemtuzumab for TCD ex vivo and/or in vivo, might
also target host monocytes and moDCs that could
drive the afferent sensitization of donor T cells against
the host. Longer lived, slower turnover, resident pop-
ulations of LCs and DDC-IDCs in the epithelia and
tissues are CD52 negative and not targeted by alemtu-
zumab. This could then account for the clinical finding
that preparative regimens using alemtuzumab ex vivo
and/or in vivo often result in less GVHD for the
same degree of T cell depletion achieved by physical
methods, even with HLA mismatching, because alem-
tuzumab additionally targets monocyte precursors and
moDCs [124]. LCs and DDC-IDCs sharing minor
histocompatibility Ags unique to other hematopoietic
cells would remain intact long enough to stimulate the
desired GVT effects mediated by the allograft [125].
Unfortunately, the use of alemtuzumab to treat
steroid-refractory GVHD after the fact has been
plagued by excessive immunosuppression ([126] and
unpublished), likely owing to the fact that it also tar-
gets effector B and T lymphocytes.
What is the nature of antigen required for
sensitization of GVT?
Tumor antigens for immunization segregate pri-
marily between those that are mutated and unique to
the malignancy and those that are shared with normal
tissues often as self-differentiation antigens. On the 1
hand, the goal is induction of immunity and the other
is to break tolerance and induce antigen-specific auto-
immunity. For induction of immunity, using more
complete antigen sources, like dying tumor cells or
mRNA of full-length antigens, is more likely to pro-
vide both types of antigen than single peptide pulsing.
So also is epitope spreading as tumor cells are killed by
DC-stimulated CTL and provide additional antigenicepitopes for crosspresentation. Overcoming tolerance
to induce controlled autoimmunity is more challeng-
ing, because the antigens are often weaker and less
immunogenic. In such cases DCs could provide the
necessary extra boost needed to stimulate an immune
response. That said, Tregs specific for shared self-
antigens are often present that may thwart attempts
to break tolerance.
How do autologous versus allogeneic transplant
platforms differ for immunotherapeutic prevention
of relapse posttransplant
For any immunotherapeutic applications of DCs,
one must choose between active immunization versus
lymphocyte sensitization ex vivo by DCs followed by
adoptive or passive immunization with the resulting
T cell effectors. Autologous HSCT therefore offers
an excellent platform on which to test active DC im-
munization against the primary malignancy. In the
early postautologous HSCT period, Tregs have been
eliminated or substantially reduced and have insuffi-
ciently recovered to interfere with active DC immuni-
zation. Prevention of relapse is also a clearcut response
assessment, given that this is 1 of the main, if not the
principal reason for most autologous HSCT failures.
Allogeneic HSCT is more challenging. Following
the transplantation of TCD allografts, there is insuffi-
cient recovery ofT cells to respond to activeDC immu-
nization. Hence, one needs to sensitize T cells ex vivo
for adoptive immunotherapy. Although many types of
APCs can be used to generate tumor antigen-specific
CTLs, most of these require multiple rounds of stimu-
lation and often substantial cytokine supplementation.
Defined DCs, in particular, CD341 HPC-derived
LCs, will generate potent CTL even against self-
differentiation tumor antigens like WT1, against
which tolerance should exist. LCs accomplish this after
short periods of culture and without the confounding
effect of exogenous cytokines [108]. For recipients of
unmodified grafts on prolonged pharmacologic immu-
nosuppression for prevention or treatment of GVHD,
the passive transfer of activated T cells is more prob-
lematic as the pharmacologic immune suppression
also compromises their function. Perhaps targeted de-
pletion of the DC subset most responsible for fueling
the fire of GVHD would reduce the need for as much
or as prolonged immune suppression, thus allowing
the transfer of tumor antigen-specific T cells with
low risk of causing broader GVH reactivity.
What is the role of DCs and NK cells for
prevention of posttransplant relapse?
NK cells would seem to provide another answer to
the challenges of preventing posttransplant relapse.
The prevention of GVHD, the support of early engraft-
ment, and the promotion of GVT have all been
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can circumvent tolerance early after transplant by
expressing inhibitory KIR for nonself-HLA and execut-
ingNKcell effector functions [129].Less is knownabout
NKT cells.We do know, however, that pDCs respond-
ing to viral infections are potent early inducers of NK
and NKT cell reactivity via production of enormous
amounts of type I interferons. We also know that
moDCs secrete the most IL12p70 upon activation, and
hence are the only conventional DC subtype capable
of stimulating resting NK cells [109]. LCs, lacking
IL12p70 but providing IL-15, cannot stimulate NK
cell reactivity, but can support their viability [109].
Returning to the theme of afferent sensitization, how-
ever, an important unknown remains with regard to
how and which DCs can influence KIR expression by
NK cells, potentially to maintain reactivity against
tumors expressing host HLA, beyond the initial wave
of autoreactive T cells.
Unanswered Clinical Challenges and Program
Initiative in Dendritic Cells and Immune-Based
Therapy
The divisions of labor among distinct human DC
subtypes achieve the most effective balance between
steady-state tolerance and the induction of innate
and adaptive immunity against pathogens, tumors,
and other harmful insults. Current approaches to ex-
ploit defined DCs for immunotherapy are still mostly
labor-intensive, although broader approaches for
loading antigens that allow DCs to process and tailor
presented peptides to their ownMHC are increasingly
promising. Conjugating antigens to specific receptors
on DCs is also yielding progress. Rodent models are
now revealing important data about distinct DC pre-
cursors, homeostasis of tissue-resident DCs, and DC
turnover in response to inflammation and pathologic
conditions like GVHD. The selective eliminating of
defined DC subsets that are responsible for GVHD,
whereas expanding those that are critical to the onset
and maintenance of GVT, represent a holy grail for
the controlled afferent sensitization of lymphocyte
responses in HSCT. Unfortunately, to date, there
are no stably tolerogenic human DCs for experimental
therapeutic use to reduce GVHD while maintaining
GVT. Eliminating the DC subtype most likely to
fuel the fire of GVHD, together with the use of defined
DC subtypes to stimulate both innate and adaptive
immunity, may prove most useful clinically.
DLIs
In the 2 decades since the first reports by Slavin
et al. [130] and Kolb et al. [131] of using of DLI to treat
patients with CML who had relapsed after allogeneic
transplantation, a large number of studies have helped
identify the diseases most responsive to DLI. Thesestudies have also established doses of DLI to be used
in defined clinical settings and exploredmethods to en-
hance the GVL effect of DLI and to limit toxicity.
These studies have established that DLI is effective
in treating MRD in some situations.
A small number of studies have addressed the role of
prophylactic DLI. Studies in this area have been lim-
ited, and a number of factors present challenges to
studying the effectiveness of DLI in this setting. First,
patients who are at sufficiently high risk of relapse after
transplantation to warrant additional therapeutic inter-
vention need to be identified.These populationsmay be
defined by disease type or state of disease at the time of
transplant, or by posttransplant factors such as persis-
tent MRD or presence of mixed chimerism. Second,
an appropriate platform forDLI needs to be established
in the context of NMA allogeneic HSCT. Several
studies have demonstrated that prophylactic DLI
administration is often precluded because patients had
developed complications after transplant. The most
common complication is cGVHD. Transplantation
performed using T cell-depleting agents such as ATG
and alemtuzumab have beenmost successful in creating
a platform for prophylactic DLI. Third, measurable
endpoints to define the success of DLI in preventing re-
lapse are needed. Traditional endpoints such as OS and
PFS may be used, but it is not clear if the conversion of
mixed chimerism to full donor chimerism may also
serve as surrogate markers of DLI activity. In this
next section, we will attempt to identify the current
role of DLI in the prevention of relapse and propose fu-
ture areas to explore.Diseases Where DLI is Effective
Registry reports from Europe and North America
have identified diseases that respond toDLI.This infor-
mation, combined with outcome data fromRIC alloge-
neic HSCT studies, have identified diseases that appear
most responsive to theGVL effect. Diseases which have
a high sensitivity toGVT includeCML, low-grade lym-
phomas, CLL, and MM. Diseases with intermediate
sensitivity include Hodgkin lymphoma (HL), AML,
and MDS. Diseases with a lower sensitivity include
ALL and large cell lymphoma.
CML
DLI has been studied most intensively in patients
withCML.Treatment in aminimal disease state is asso-
ciated with improved outcome. Studies consistently
demonstrate that patients with CML in more advanced
stages of relapse, accelerated phase, or blast crisis, have
a much lower response rate following DLI [132]. An
analysis of 593DLI demonstrated responses for patients
with CML in molecular relapse, cytogenetic relapse,
chronic phase, and accelerated/blastic phase relapse
were 100%, 90%, 75%, and 35%, respectively [133].
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pear to be durable. Studies have reported low relapse
rates as low as 9% for patients receiving DLI [134].
The 3-year OS for this group of patients was 95%.
When relapse does occur, isolated extramedullary in-
volvement without evidence of systemic disease can be
observed. The mechanism of ‘‘immune escape’’ for cells
in thesemyeloblastomas is not clear.DLI is also effective
in treating patients with CML relapsing after unrelated
donor transplant [135]. The degree of donor chimerism
at the time of DLI is not predictive of response in
patients with CML. Although a high degree of donor
chimerism was associated with a more rapid response,
patients with \10% donor chimerism at the time of
DLI had a similar complete remission rate as patients
with high degrees of donor chimerism at the time of
DLI [136].
T cell dose also appears to affect both response rate
and risk of development of GHVD. Prospective trials
of unmanipulated DLI have analyzed T cell number
and the impact on response and GVHD. Studies
have demonstrated high response rates and a low inci-
dence of GVHD in patients receiving 1  107 CD31
cells/kg [137]. A subsequent trial demonstrated that
GVHD was significantly lower with the escalating
dose regimen (10%) compared with the single bulk
infusion (44%) (P 5 .011) [138].
The role of additional agents combined with DLI
is not clear. The addition of alpha-interferon allowed
much lower doses of donor cells to be infused and
was associated with similar response rates to those
seen with higher cell doses [139]. Imatinib and DLI
have also been explored, although data is limited [140].
MM
The overall response rate to DLI in patients with
MM that has relapsed approaches 45%, with complete
responses noted in about 25% of patients. Both dose
of cells infused and timing of DLI after transplantation
for MM may influence response rates. When treating
relapse, patients receiving .1  108 CD31 cells/kg
had an improved response; however, responses have
been noted in patients with infusion of doses as low as
1  107 CD31 cells/kg [141]. Early administration of
DLI after allogeneic transplantation may improve re-
sponse rates and improve the graft-versus-myeloma ef-
fect after transplantation.
Prophylactic DLI has been explored in patients
withMMafterMA transplantation. In 1 study, prophy-
lactic DLI was given to 14 MM patients 6 to 9 months
after T cell-depleted MA allogeneic HSCT [142].
Eleven of the 14 patients receiving DLI had evidence
of disease at the timeofDLI,with 10demonstrating sig-
nificant GVT responses and 6 obtaining complete re-
missions. A limitation of this study was that only 58%
of the patients were able to receive DLI after transplan-
tation. Patients could not receive DLI if they haddeveloped complications such as GVHD limiting the
utility of this approach. Using a similar strategy after
an in vivo T cell-depleted allogeneic RIC HSCT,
DLI was administered to patients with residual or
progressive myeloma [143]. Fourteen of 20 patients
received escalating dose DLI for residual/progressive
disease more than 6 months posttransplant. Fifty per-
cent of patients had a clinical response. Significant fac-
tors associated with response included the development
of aGVHD and cGVHD. A common finding among
studies is that not all responses are durable, suggesting
the need for either repeat DLI or other agents.
DLI combined with other immune modulator
agents has been explored in hopes of improving the
response toDLI.Low-dose thalidomide incombination
with DLI in patients with relapsed myeloma resulted in
anoverall response rate of 67%and a complete response
rate of 22% [144]. Limited toxicity was observed with
only 11% of patients developing evidence of cGVHD.
The safety and efficacy of combining bortezimib or
lenolinomide with DLI will need to be explored in
clinical trials.
Myelodysplastic syndromes and acute leukemias
The results of DLI in patients with relapsed acute
leukemias and MDS have not been as encouraging as
in patients with CML and MM. Administration of
chemotherapy followed by DLI did not improve the
outcome for patients who had relapsed after transplant
and was associated with significant toxicity.
Studies using prophylactic DLI are starting to
emerge. Forty-six patients with AML received pre-
emptive DLI 120 days after transplant if they were
off immune suppressive medications and there were
no contraindications [145]. Improved survival was
noted in the patients receiving DLI compared with
case-matched controls. DLI may be combined with
other active agents such as decitibine; however, limited
data is currently available.
DLI is associated with a low response rate in ALL.
In patients who respond, the duration of response is
limited. There is some suggestion that T cell diseases
may respond better to DLI.
CLL and lymphomas
DLI experience in patients with CLL and low-
grade (follicular) lymphomas is emerging. Treatment
of patients with CLL in aminimal disease state appears
to be associated with improved outcome [146]. Seven
of 9 patients with CLL achieved durable molecular
remissions following DLI. Data of the efficacy of
DLI in more advanced lymphomas are lacking.
EBV-associated lymphoproliferative disorders
after HSCT
DLI is a highly effective treatment for posttrans-
plant EBV-associated lymphoproliferative disorders
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received DLI at a dose of 1.0  106 CD31 T cells per
kilogram and a 100% pathologic and clinical response
was noted without significant GVHD [147]. As an
extension of this strategy, researchers have now dem-
onstrated that administration of in vitro cultivated
EBV-specific CTLs alone is sufficient to eradicate
EBV-LPD [148–150]. PCR tests are now available
that can quantify EBV DNA and offer a method of
diagnosing patients prior to the onset of clinically
evident EBV-LPD [151]. With this tool for early de-
tection, prophylactic administration of EBV-specific
CTLs can now be used as preemptive therapy against
EBV-LPD after BMT [149,150]. DLI has also been
used to treat other viral illness such as human
herpesvirus-6 encephalitis [92].
DLI after NMA and RIC Allogeneic HSCT
The role of DLI after RIC allogeneic HSCT re-
mains to be defined. DLI has been used after RIC allo-
geneic HSCT in 2 ways: (1) treatment of persistent or
relapsed disease, or (2) as a method to convert patients
from a mixed chimeric state to full donor chimerism.
Use of DLI after RIC allogeneic HSCT has been
limited by the high incidence of cGVHD seen after
non-TCD RIC allogeneic HSCT, which commonly
develops as immune suppression is tapered. Trials
exploring DLI administration while patients are on
immune suppressive medications have not been per-
formed, and their safety and efficacy are uncertain.
Prophylactic DLI has been more successfully used
after TCD transplantation. When anti-T cell agents
such as alemtuzumab or ATG are used as part of the
RIC regimen, the incidence of recurrent disease after
transplantation is increased, and many patients demon-
stratemixed chimerismafter transplantation.The riskof
developing GVHD is also reduced, thus allowing for
more patients to receive DLI. A strategy of using
dose-escalated DLI in this setting has been shown
tobeassociatedwith a low incidenceofGVHD,whereas
inducing GVT effects in a variety of diseases [143,152].
These studies have also demonstrated that mixed
chimerism can be converted to full donor chimerism
using DLI. In an effort to limit toxicity related to DLI,
another approach focused on prophylactic CD81 T
cell-depleted DLI after NMA allogeneic HSCT[153].
In that study, 11 of 23 patients were able to receive pro-
phylacticDLI.Patients receivingCD81Tcell-depleted
DLI demonstrated accelerated immune reconstitution
and minimal GVHD.
Methods to Enhance the GVT Response
Mediated by DLI
Strategies to enhance the GVT effect mediated by
DLI have included infusion of activated cells as well as
methods to improve potential target antigen presenta-tion. Infusion of antigen specific cells in diseases such
as CML also have the potential to increase efficacy
while limiting toxicity. As previously described, selec-
tive populations of cells, such as CD81T cell-depleted
DLI, have been explored and appear to be associated
with a reduced incidence of GVHD without compro-
mising the efficacy of DLI.
Regulatory T cells (Treg) are naturally occurring
CD41CD251FOXP31 T cells that constitute approxi-
mately 5% to 10% of the circulating CD41 T cell
population and dominantly suppress autoreactive lym-
phocytes and control immune responses [154,155].
Treg suppress both the innate and the adaptive
immune systems [156–158]. A trial to assess whether
Treg depletion may enhance the immunologic GVT
effect of DLI is currently ongoing in patients who
have relapsed after transplant. Preliminary results
demonstrate a .2-log depletion of CD41CD251
FOXP31 cells has been achieved. The cell infusions
are well tolerated, and minimal GVHD has been
observed. Results from this trial, if successful, may
inform the use of a similar strategy in patients prior to
relapse.Unanswered Clinical Challenges and Program
Initiatives in DLI
Defining the risk of relapse is critical to the devel-
opment of future studies of DLI. Both data for single
institutions and cooperative databases will help define
potential candidates for prophylactic DLI studies.
This information should identify populations at high
risk for relapse. Understanding the kinetics of relapse
will be equally important. Differences based on both
disease type and disease status at the time of transplant
will have an impact on the kinetics of relapse and define
the time interval available for intervention. MRD
monitoring, which is available in certain diseases,
may serve as a powerful tool to identify appropriate pa-
tients for clinical trials. In diseases where a significant
GVT effect has been demonstrated, DLI using current
methods may be sufficient, although a better under-
standing of dose and time of administration is needed.
In diseases where GVT is less effective, novel
approaches to enhance the efficacy of DLI through
vaccines or target specific DLI should be explored.
Another challenge is to define the appropriate plat-
form for prophylactic DLI in the RIC and NMA set-
tings. The majority of trials of prophylactic DLI
reported to date are in patients who have received
TCD transplantation. Despite TCD, a number of pa-
tients are still not able to receive DLI because they
have developed posttransplant complications or expe-
rience early progression of their disease. Future studies
will need to define dose, timing, and composition of
cells to be infused in the T depleted setting. DLI in
the non-TCD setting has been limited to patients
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therapy. It may be reasonable to explore the safety
and efficacy of administering DLI while patients are
on immune suppression as a method to enhance the
efficacy of DLI.
The durability of DLI is not clear, and there is
a need to explored maintenance immune therapy.
Risk of relapse after DLI varies by disease. Future
strategies may need to explore repeated DLI to main-
tain remission. Extramedullary sites of relapse have
been noted after DLI. As there is a better understand-
ing of what factors play a role in this pattern of relapse,
DLI strategies will need to change.
A significant effort should be directed toward
exploring DLI combined with other promising thera-
peutic interventions. Future trials should combine
DLI with disease-modifying agents in diseases such
as MDS/AML and MM. Selected T cell infusions, ac-
tivated, and antigen-specific T cell infusions are also
possible areas of study. DLI may also be explored in
augmenting responses to vaccines. To date, neither
the dose, timing, nor cell type have been explored.
Finally, defined endpoints for clinical trials of DLI
need to be established. OS and PFS are the most im-
portant endpoints in a randomized trial, but these
types of trials will be difficult to perform outside of
a cooperative group setting. For smaller trials, these
endpoints can only be used in well defined, homoge-
neous populations, where there is well-documented
historic control data. Elimination of MRD can serve
as a surrogate when available. The persistence of
MRD without progression to relapse after DLI may
challenge our preconceived notion that disease must
be completely eliminated. It may force us to consider
a disease state where the disease is suppressed but
not eliminated by the donor’s immune system. In
such cases, time to relapse would be the most impor-
tant endpoint. Chimerism as a surrogate endpoint is
also possible in some diseases. Data support that
high levels of donor chimerism are associated with im-
proved outcome in some diseases. In other diseases,
high levels of donor chimerism do not appear to have
an impact on risk of relapse, suggesting that the
GVT effect and the graft-versus-hematopoiesis effect
in these diseases are distinct. Augmenting donor chi-
merism byDLI when patients are off immune suppres-
sion or perhaps converting low donor chimerism to
high donor chimerism early after transplant by DLI
should also be explored.T CELL ENGINEERING
The ability of adoptively transferred T cells
administered as DLI following allogeneic BM trans-
plantation to induce long-term remission in some
hematologic malignancies, as reviewed above, is wellestablished [159]. The reasons why CML responds
well to this therapy, whereas ALL and AML do not,
are still poorly understood. Whether the resistance
of the latter is because of poor tumor antigen recogni-
tion or themalfunction of tumor-reactive T cells in the
tumor microenvironment, or both, T cell engineering
offers an exciting prospect for overcoming these defi-
ciencies. The advent of efficient methods for human
T cell engineering has opened the possibility of intro-
ducing antigen receptors into T cells and thus to rap-
idly generate tumor-reactive T cells. Gene transfer can
be easily performed in readily accessible peripheral
blood T lymphocytes. Over the past decade, T cell
engineering has mostly focused on redirecting T cell
antigen specificity, which is normally determined by
the TCR. Although the TCR is the physiological
receptor and the preferred tool for some investigators,
other investigators have focused on chimeric antigen
receptors (CARs) [90], which are artificial structures
designed to ligate cell surface antigens and provide
activating and costimulatoty signals to T cells. In
addition to tumor targeting, T cell engineering addi-
tionally provides a means to augment T cell function
and/or overcome tumor escape mechanisms that
stifle T cell responses. The latter include HLA
downregulation, which deprives the T cell antigen re-
ceptor of a ligand on the tumor cell [160,161], the
intratumoral accumulation of regulatory T cells and
myeloid tumor cells [162], and the expression by tumor
cells of various suppressive molecules such as prosta-
glandin E2, TGF-b, or B7x (Table 1) [159,160,162].
Peripheral blood T cells can be retargeted to any
chosen tumor antigen by the genetic transfer of an
antigen-specific receptor. The transduced receptors
may be either HLA-restricted, heterodimeric TCRs,
or CARs that typically recognize native cell-surface
antigens. Considerable progress has been made in
recent years to address the challenges posed by the
transfer of either receptor type. Vector and protein
modifications enable the expression of TCR chains
in humanT cells at functional levels andwith a reduced
risk of mispairing with endogenous TCR chains. The
combinatorial inclusion of activating and costimula-
tory domains in CARs has dramatically enhanced
the signaling properties of the chimeric receptors de-
scribed over a decade ago. Based on effective T cell
transduction and expansion procedures now available
to support clinical investigation, improved designer
TCRs and second generation CARs targeting an array
of antigens, including CD19 and WT-1, are ready to
be evaluated in a range of hematologic malignancies.TCR Gene Transfer
The clonotypic ab or gd heterodimer borne by
every T cell associates with the CD3 complex, itself
comprising g, d, 3 and z chains. T cell activation is
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of the TCR on the MHC-peptide complex borne by
the antigen-presenting cell (APC). Because all T cells
naturally express their own TCR, TCR transfer into
mature lymphocytes sets the stage for competition
and recombination between the 2 TCRs. Much re-
search over the past few years has focused on how to
appropriately express a second TCR in T lymphocytes.
Transgenic TCR expression
TCR function is known to be dependent on its
level of expression, which is limited by the amount of
available CD3 complex [163]. Following gene transfer,
the transduced TCR must compete with the endoge-
nous TCR for association with CD3. Although differ-
ent a/b chain heterodimers seem to intrinsically differ
in their competitiveness vis-a`-vis the endogenous
TCR [164,166], a key point is to ensure high-level
expression of the transduced TCR. Much progress
has been accomplished in this area, based on improve-
ments in transcription, dual chain coexpression, and
codon optimization. Several retroviral enhancer/pro-
moters have been compared in terms of their promoter
strength, cell cycle dependence, and susceptibility to
transcriptional inactivation or silencing. Long-term
in vivo comparisons are still lacking. The need to coex-
press 2 chains is best addressed using bicistronic vector
designs, which can be achieved by using either viral
internal ribosomal entry sites (IRES) [161] or 2A
elements [166,167] to link the 2 open reading frames.
Finally, codon optimization has been shown to
improve cell surface expression of several TCR
heterodimers [168–170].
Controlled TCR pairing
The reassortment of transduced and endogenous
TCRchains is amajor concern in this approach, because
the coexpressionof 2a- and2b-chainsby the sameTcell
could theoretically result in the formation of 4 different
TCRs, raising the prospect of inducing autoimmunity.
Several molecular and cellular approaches have been
proposed to resolve this issue. The first rests on the in-
corporation of murine constant regions into the TCR,
which results in higher cell surface expression and de-
creasedmispairing with the endogenousTCR in human
T cells [167,171,172]. The immunogenicity of such
chains is a concern, but no TCR immunogenicity was
observed in the first clinical study making use of such
receptors [173]. The second approach is to introduce
cystein bonds into the a- and b-chains, which are de-
signed to favor dimerization of the transduced TCR
[174–176]. Although variable, this approach may
ultimately solve this concern, and poses a lesser risk of
immunogenicity than the use of extended murine
sequences. An alternative, nonmolecular approach is to
utilize gd T cells for adoptive therapy, in which abheterodimers can be introduced without the concern
of heterogeneous pairing [177,178]. It is presently
unknown whether gd T cells will function and persist
aswell asabTcells in the adoptiveTcell therapy setting.CAR Gene Transfer
The first generation of CARs utilized the CD3z
cytoplasmic domain to elicit T cell activation. How-
ever, it was not until costimulatory properties were in-
corporated into the next generation of CARs that
a greater strength and quality of antigen-induced
signaling could be provided to T cells. An impressive
array of second generation CARs has been developed
in the past decade.
Antigen recognition by CARs
Most CARs typically utilize an antibody-derived
antigen-binding motif to recognize antigens. Some
utilize receptor or ligand domains as their targeting
moiety, such as heregulin [179] or IL-13, which bind
to their cognate ligand or receptor counterpart. All of
these CARs recognize native cell-surface antigens inde-
pendently of antigen processing or MHC-restricted
presentation. Importantly, CARs therefore do not
have to be matched to the patient HLA, and can recog-
nize tumors that have downregulated HLA expression.
The molecules targeted by CARs include proteins,
carbohydrates, and glycolipids. Most current CARs in-
corporate an scFv derived from a murine mAb, but
some have been selected from phage display libraries.
The rules for identifying the best-suited scFv for a par-
ticular target molecule are not yet fully elucidated.
CAR signaling
The first CARs were reported as receptors capable
of redirecting the cytotoxic activity of CTL clones and
hybridomas. The emergence of CARs enabling T cells
to survive repeated antigenic stimulation came with
the development of CD28-CD3z dual-signaling re-
ceptors. These receptors increased IL-2 secretion in
response to antigen and permitted absolute expansion
of retargeted T cells in response to antigen in the ab-
sence of exogenous costimulation [180]. A number of
CD28/CD3z fusion receptors have been reported,
which utilize different domains and fusion points. A
side-by-side comparison of different receptors ex-
pressed at similar level in the same cells type has not
yet been reported. New fusion receptors are emerging.
Triple-fusion receptors that encompass CD3z, CD28,
and 4-1BB signaling motifs appear to enhance in vivo
effector functions relative to the dual-fusion receptors
[181,182]. These are promising receptors, but more
studies are needed, including in vivo studies, to assess
their therapeutic potential and safety profile. What is
clear is that second-generation CARs have consider-
ably superior signaling properties compared to their
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perspectives for the therapeutic use of CARs.
The T Cell Engineering Process
T cell engineering begins with the selection of ad-
equate gene transfer tools and T cells. Whereas many
tools are now available to genetically modify human T
cells, the T cell type best suited for use in adoptive
therapies remains to be defined. A key aspect of adop-
tive cell therapies is how to activate and expand T cells
to generate large numbers of T cells without impairing
their function or life span.
Methods for gene transfer
Several vector types are now available for efficient
transductionofhumanprimaryT lymphocytes.Gamma-
retroviral vectorspseudotypedwith theGibbonApeLeu-
kemia Virus Envelope were the first to permit efficient
transduction [183–185]. Transduction conditions using
mitogen- or antigen-activated T cells have since been
highly optimized bymany investigators and are currently
in use in several clinical trials. Lentiviral vectors have also
been usedwith success [186–188]. In contrast to gamma-
retroviral vectors, these do not require cell division for
stable gene transfer, but cytokine pretreatment is none-
theless a prerequisite [189–191]. Comparisons of vector
silencing or vector safety are still lacking. Whereas
lentiviral vector have an inherent reduced risk of
transforming hematopoietic progenitors in comparison
to gamma-retroviral vectors [192], it is presently
unknown whether this difference extends to T cells. In
contrast to hematopoietic progenitors, T cells are diffi-
cult to transform in mice [191,193]. Stable gene
transfer may also be attained using nonviral transposon/
transposase systems [194], but the efficacy and safety of
this approach still needs to be worked out. Transient
systems have also been optimized, using electroporated
DNA or RNA encoding TCRs [195,196]. These rapid
and efficient systems are useful for basic studies, but it
is uncertain whether the short duration of transgene
expression will be useful in clinical applications.
Transferring the right T cell subset
There is much debate what T cell type, in terms of
its differentiation stage [80], may be the most effective.
It appears that highly lytic, activated effector T cells are
not the most active in vivo [197]. Ongoing research by
several investigators aims to compare the relativemerits
of TN cells, central memory cells, and virus-specific T
cells. The former are endowed with the greatest differ-
entiationpotential [198], but centralmemoryTcells are
imprinted at the time of their initial activation to
acquire survival properties that ultimately prolong their
function [199,200]. Virus-specific memory T cells that
are chronically reactivated by antigen, such as EBV-
reactive T cells, may also serve as effective cellular vec-tors for tumor-reactive TCRs and CARs [163,201].
More studies are needed to define the relative
advantages of these different subsets. Alternative T
cell subsets, such as gd T cells and NKT cells, are still
little known. Another twist on this approach is to
utilize lymphoid progenitors, which become tolerant
of the host in which they develop and can be
genetically redirected to tumor antigens [70,202,203].
Methods for T cell expansion
Beyond the T cell purification and transduction
steps, the T cell expansion process is of critical impor-
tance. Indeed, T cell proliferation does not occur
without affecting T cell differentiation, and hence,
the functional and survival potentials of the cells to
be adoptively transferred. The provision of adequate
activating and costimulatory signals during the expan-
sion is essential to generate effective T cells. The de-
sign of artificial antigen-presenting cells (AAPCs)
holds the promise to yield optimized antigen-specific
stimulators [204–208], as well as nonspecific T cell
amplifiers [209–211]. Panels of AAPCs expressing
common HLAs have recently been reported, which
express single HLA molecules and should be useful
to generate appropriately restricted CTLS, especially
in the haploidentical transplant setting [212]. These
cellular systems are poised for clinical investigation.
Clinical grade antibody-coated beads are already
available and currently in use for the activation, trans-
duction, and expansion of T cells in protocols in leuke-
mia and prostate cancer [213]. This remains a vital area
of investigation that will play a decisive role in the
development of effective, safe, and affordable T cell-
based therapies.Clinical Trials
Clinical studies ttilizing first-generation CARs
Completed clinical studies are limited to phase I
studies evaluating first-generation CARs targeting the
folate receptor in ovarian cancer [214], carbonic anhy-
drase in renal cancer [215], CD20 in lymphoma, and
GD2 in neuroblastoma [201]. The clinical responses
have overall been very modest, with the exception of
1 partial response in the neuroblastoma study. Immu-
nogenicity of CARs was observed in the first 2 studies,
but not the latter 2. These studies utilized first genera-
tionCARs and suboptimalT cell expansion procedures
such as OKT3-mediated T cell expansion. The field is
thus keenly awaiting studies that utilize second-
generation CARs and improved T cell expansion
procedures that provide appropriate costimulation
and cytokine stimulation prior to T cell infusion. Stud-
ies targeting CD19 are especially awaited as these hold
the promise of activity in several B cell malignancies. At
least 7 trials targeting CD19 with second-generation
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Europe, most of which utilize a CD19-CD28z CAR.
Other investigated targets include CD20, CD23,
CD33, and CD74.
Clinical studies utilizing TCR gene transfer
Two clinical studies utilizing TCR gene transfer
have been reported to date, both in melanoma. Mor-
gan and his colleagues [216] at the NCI were the first
to establish the feasibility of this approach. Having
transferred an HLA A2.1restricted, MART-1-specific
TCR in peripheral blood T cells of patients with
metastatic melanoma, the obtained partial responses
in 2 the first 15 treated patients showed partial re-
sponses. Utilizing a higher affinity MART-1-specific
TCR to treat another 36 patients with metastatic lym-
phoma, the same groups recently reported objective
cancer regressions in 30% and 19% of patients who
received the human or mouse TCR, respectively
[173]. However, patients exhibited destruction of
normal melanocytes in the skin, eye, and ear, which
subsided with steroid treatment. These encouraging
results point to the possible efficacy of this approach,
as well as the risk of on-target secondary effects with
some if not all nontumor-specific antigens. WT-1 tar-
geting is currently under study by several groups.
Other investigated antigens include minor histocom-
patibility antigens and cancer-testis antigens.Perspectives and Challenges
T cell engineering is a rapidly evolving field of re-
search that aims to provide tumor-targeted T cells for
all patients and to generate T cells with enhanced
antitumor function. Effective tools for genetic engi-
neering are now available, and significant advances
have been made to express transduced antigen recep-
tors at functional levels in human T lymphocytes.
Both ab heterodimeric TCRs and CARs show great
promise for redirecting T cell specificity. CARs are at-
tractive because they are not restricted by HLA, but
their signaling function does not benefit from the sup-
port provided by the CD3 complex. However, CARs
with vastly enhanced signaling properties have been
developed in recent years.
A large number of clinical trials using either anti-
gen receptor type are on the verge of opening in the
United States, Europe, and Japan. The multiplicity
of trials targeting CD19 in B cell malignancies will
provide the ground for comparing the effectiveness
of different vector designs and T cell expansion
processes. The identification of the best-suited T cell
subsets to engineer and the advent of novel tools
such as AAPCs will likely contribute to further en-
hance the efficacy of this approach in the near future.
Although the design of recombinant antigen recep-
tors and the ability to transduce various T cell subsetshas made great strides in the past few years, the clinical
experiencewith these new tools is still very limited.The
first evidence of efficacy is emerging [173,201,217], and
so is the potential for toxicity [218–220]. The
relationship between antigen receptor design, T cell
dose, T cell type, conditioning, tumor burden, and
disease type or stage is presently unknown. Much
more clinical investigation is needed to gain concrete
insights into this complex immunopharmacology. An
additional challenge will be to ‘‘export’’ technologies
from 1 medical center to another, which is essential
for the objective evaluation and greater accrual of
patients on trials that otherwise run the risk of
remaining local phenomena. This will require strong
support from funding agencies, not only to support
research, manufacturing, and clinical investigation
but also regulatory and legal to lift the obstacles to
exchanging manufactured cell products between
collaborating institutions.THE ROLE OF VACCINATION IN THE
PREVENTION OF RELAPSE
Despite the early identification of tumor antigens as
transplantation antigens [221–225], cancer immunity
remains poorly understood in the allogeneic HSCT
setting. In part, this is because transplantation brings
more complexity to the challenge of determining how
host immune cells distinguish ‘‘self’’ and ‘‘nonself’’
[226,227], and it expands the number of possible
interactions of recipient- and donor-derived cells in
priming and maintaining tumor immunity. Yet, the
rich experience of allogeneic transplantation offers
perhaps the strongest clinical evidence that active tu-
mor immunity can rid patients of malignant cells such
as leukemia and prevent relapse [228,229]. If the
critical cells and molecular events that drive the GVT
effect were better understood, for example, rational
immune therapy strategies might be devised that
deliver the ‘‘Holy Grail’’ of allogeneic HSCT:
induction of GVT without GVHD. Nevertheless, it is
still early in our understanding of the biological basis
of this immunity, and for turning that ‘‘actionable
intelligence,’’ in present jargon, into targeted immune
therapy approaches to improve clinical outcome by
preventing relapse after HSCT.
Vaccines are 1 treatment approach with the poten-
tial to selectively boost GVT. Inducing or enhancing
host and donor immunity against malignant cells by
vaccination is an old idea [230], but it offers many
theoretical advantages over existing treatments. For ex-
ample, they are relatively safe.Theyare antigen-specific,
with the potential to reduce the risk of GVHD. They
may be used to treat existing disease as well as prevent
relapse by inducing long-term and possibly life-long
immunity. They can be administered to both donor
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combine vaccination with cell therapies might be
applied in a staged approach to first prime immunity
in the donor, followed by adoptive transfer of primed
donor-derived lymphocytes to transplanted recipients,
and then further vaccination of the recipient to sustain
the transferred donor-derived immunity. Because vac-
cines are less toxic than most other treatments, they
could be combined with other drug therapies, such as
targeted single-agent drugs in complementary or addi-
tive strategies in the posttransplant setting. Finally,
eliminating GVHD may not be necessary, and it may
not be beneficial. Allogeneic immune responses that
drive GVHD, which may not be directed specifically
at tumor or tumor tissue-derived antigens, may none-
theless heighten overall immunity by increasing chemo-
kine or cytokine expression [231], thereby indirectly
driving GVT [232]. This mechanism is supported by
the clinical observation that GVT often occurs in the
setting of GVHD [233,234]. Therefore, rather than
excluding GVHD patients from clinical vaccine trials,
the heightened immunity from low-grade GVHD
might produce a more favorable milieu for eliciting
GVT by vaccination in patients that do not require
steroids, for example.
Despite these potential advantages, cancer vaccines
thus far have not produced significant clinical results
[235]. Most vaccine trials have involved patients with
solid tumors treated outside the transplant setting.
However, several observations can be drawn from our
failures thus far, including the identification of mecha-
nismsof tolerance and anergy. For instance, tumors can
escape immunity by decreasing MHC expression,
tumor antigen expression [236], or by the emergence
of cells withmutated antigens that are no longer recog-
nized by T cells [237]. Nevertheless, appropriate
antigen selection and increasing antigen expression
by drug treatment might overcome these problems
[238]. Furthermore, when specific immunity is induced
by vaccination, it ismost often in the setting ofMRD, in
part because host immune deficits, such as broad
anergy, may not yet have developed. Alternatively,
antigen-specific immune tolerance may also develop
in the setting of high tumor burden, such as in patients
that overexpress the leukemia-associated antigen pro-
teinase 3 (P3) and the P3-derived epitope PR1 [239].
For example, CML cells that overexpress P3 induce
selective apoptosis of high affinity PR1-specific T cells,
thereby eliminating the most effective T cells against
CML and creating tolerance by deletion, favoring the
outgrowth of leukemia.
A critical factor when considering the lackluster
results of cancer vaccines is that the trials have been
designed as therapeutic rather than preventative, in-
volving patients with large tumor burdens, including
many with metastatic disease. Historically, however,
vaccines have been most successful in the preventionof infectious diseases such as pneumonia or influenza,
but this approach has not been well tested in the cancer
setting largely because of the lack of a sufficiently im-
munogenic vaccine preparation and the failure to test
vaccines in a healthy patient population. In part, this
is because of a fear of inducing side effects in patients
who may have minimal disease or no disease yet at all.
For example, cancer vaccines have largely been com-
prised of self-antigens or tumor-specific antigens that
have similarity to self-antigens and the trials have
therefore been focused on phase I testing in patients
that already have cancer to avoid complications such
as autoimmunity, despite evidence that autoimmunity
may be beneficial [240,241]. However, the allogeneic
transplant setting offers a potential advantage to test
whether leukemia vaccines may be useful in primary
and secondary prevention because vaccines comprised
of hematopoietic-restricted minor histocompatibility
antigens (mHAgs) would be unlikely to induce immu-
nity against donor hematopoietic cells in the recipient.
The preventive setting is well-suited to testing cancer
vaccines, however. The recently approved HPV vac-
cine [242], for example, is used to prevent cervical
cancer, although therapeutic vaccines are also being
developed for this disease [243,244].
Vaccines for hematologic malignancies have only
recently been explored, mostly in the setting of mye-
logenous leukemias and MDS. The identification of
mHAgs, leukemia-specific antigens, and leukemia-
associated antigens has facilitated such trials. Although
it is beyond the scope of this review to examine all po-
tential vaccine targets, it is worthwhile to describe
some as examples.
The allogeneicGVTeffect is closely associated with
donor T cells, although alloreactive NK cells [245] are
also involved in anti-AML effects [246,247]. T cells, as
mediators of the adaptive immune response, recognize
specific peptides within the peptide-binding groove of
self-MHCmolecules, and mHAgs are an obvious target
ofGVLin theHLA-matchedSCTsetting.Ubiquitously
expressed mHAgs such as HY [147,248], HA-3, HA-4,
HA-6, HA-7 [249], and HA-8 [250] may play a role in
both GVHD and GVT effects. mHAgs exclusively
expressed on recipient cells of hematopoietic origin,
however, such as HA-1 and HA-2 [251] or on lineage-
specific hematopoietic cells such as HB-1 [252] may re-
sult in GVT reactivity in the absence of severe GVHD.
T cells recognizing hematopoiesis-restricted mHAgs
may induce a relatively specific immune response against
malignant hematopoietic recipient cells and induce noor
only minor GVHD [253]. Despite this potential, how-
ever, the requirement for identical HLA matching and
for selective mHAg mismatching of low-frequency
minor alleles imposes practical limits on the broad clin-
ical implementation of mHAg-based vaccine strategies.
Therefore, vaccination with leukemia-associated anti-
gens may also be considered.
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involved in apoptosis, cell proliferation, and organ
development [254].WT-1 is overexpressed inmany tu-
mors including lymphogenous andmyelogenous leuke-
mia, and it has been strongly linked to leukemogenesis
[255]. A number of putative HLA-binding motifs have
been documented within the WT-1 protein, some of
which bind relevantHLA allele and elicit a peptide spe-
cific CTL response [256]. Xue and colleagues [257]
modified the TCR in a leukemia mousemodel to target
WT-1 and demonstrated the ability of these cells to kill
leukemia cells and produce cytokines in vitro. Subse-
quent administration of TCR-transduced T cells to
nonobese diabetic/severe combined immunodeficent
(NOD/SCID) mice harboring human leukemia cells
showedeliminationof leukemia in animals that received
the WT-1-specific CTL, compared with controls.
Tsuji et al. [258] transduced TCR genes obtained
fromWT-1 peptide-specificCTL into polyclonally ac-
tivated Th1 and CTL. TCR gene-modified CTL and
Th1 cells showed cytotoxicity, as well as IFN-g and
IL-2 production, in response to WT-1-expressing
leukemia targets. Thus, TCR gene modification may
provide the means to generate leukemia-specific CTL
for use in AML immunotherapy.
Early clinical studies showed that WT-1-specific
T cells could be elicited in AML and MDS patients
following vaccination withWT-1 peptide, and clinical
effects were noted during the induction of these CTL
in peripheral blood [92]. A phase I/II trial reported
CR in an HLA-A2 patient with relapsed AML who re-
ceived 4 biweekly and then monthly vaccinations with
WT-1 peptide plus the T helper protein keyhole lim-
pet hemocyanin (KLH), and granulocyte macrophage-
colony stimuating factor (GM-CSF) for a total of 15
vaccinations [259]. More recently, Scheibenbogen
and colleagues [260] reported the results of a phase
II trial of sixteen HLA-A2-positive patients with
AML and 1 patient with MDS who received up to 18
vaccinations (median 5 8) of WT-1 peptide with
KLH and GM-CSF. Twelve patients had elevated
blast counts at study entry and 5 patients were in CR
with a high relapse risk. In patients with elevated blast
counts, 6 demonstrated evidence of antileukemia activ-
ity; 1 patient achieved CR for 12 months. Further-
more, tetramer and intracellular cytokine staining
demonstrated WT-1-specific T cell responses in
peripheral blood and BM.
PR1, another leukemia-associated antigen, is an
HLA-A201 restricted nonomer peptide (VLQELN-
VTV) that is derived from the differentiation stage-
specific neutral serine proteases P3 and neutrophil
elastase (NE),which share 54%amino acid (aa) sequence
homology and are normally stored in primary azurophil
granules ofmyeloid progenitor cells [261]. The pre-pro-
forms of both proteins contain a 25-aa leader sequence
that traffics them to the endoplasmic reticulum for pro-cessing and enzyme activation [262,263]. P3 andNE are
aberrantly expressed in myelogenous leukemia (2-5-fold
higher versus normal cells) and rheumatologic disorders
such as Wegener’s granulomatosis and small vessels
vasculitis [248,263–265]. The leukemogenic and
immunogenic properties of these proteins, the latter
demonstrated by their essential role in generating
autoimmunity characteristic of the aforementioned
rheumatologic diseases, makes them ideal targets for
the development of antileukemia immunotherapy.
PR1-specific CTL that recognize and kill PR1 express-
ing HLA-A2 CML cells have been correlated with clin-
ical responses to IFN-a2b therapy in 11 of 12 patients
with CML; in contrast, PR1-specific CTLs were absent
in all nonresponders (n 5 7) [261,267]. Similarly,
PR1 specific CTLs were detected in 6 of 8 patients
with CML receiving allogeneic HSCT, whereas they
were absent in patients who failed to respond to
allogeneic HSCT and in those who received cytotoxic
chemotherapy.
A Phase I/II vaccine study in patients with refrac-
tory or relapsed myeloid leukemia has been conducted
which combined PR1 peptide and GM-CSF in 15
CML and AML patients with progressive disease.
PR1-speicfic CTL, measured using PR1/HLA-A2
tetramers, were detected in 8 patients, 5 of whom ob-
tained a clinical response [268]. In further follow-up,
a total of 66 patients (AML, CML, and MDS) have
been treated with the PR1 peptide vaccine and im-
mune responses were noted in 54%, which correlated
with clinical responses including complete molecular
remission of t(15;17) AML, inv(16) AML, and t(9;22)
CML assessed by RT-PCR [269]. The effectiveness
of peptide vaccination for inducing T cell immunity
and clinical responses has also been shown in a separate
trial conducted at the National Institutes of Health by
Rezvani and coworkers [93]. WT-1 and PR1 com-
bined vaccination resulted in immune responses in 8
of 8 patients with myelogenous malignancies and a re-
duction of WT1 RNA in some patients as a marker of
MRD. Importantly, clinical responses in both trials oc-
curred more frequently in patients with low leukemia
burden or MRD.
As another example of a leukemia-associated anti-
gen, the receptor for hyaluronic acid (HA)-mediated
motility (RHAMM, or CD168) has also been used as
a target for vaccine therapy for AML. RHAMM is
a glycophosphatidylinositol (GPI)-anchored receptor
that is involved in cell motility [270]. In addition, it
is oncogenic when overexpressed, is critical for ras-
mediated transformation [271], and has been reported
in blasts of more than 80% of patients with AML,
MDS, and MM [272]. In a phase I/II vaccine study,
clinical and immunologic responses were noted
following administration of RHAMM R3 peptide
emulsified with incomplete Freund’s adjuvant and
GM-CSF to patients with AML, MDS, and MM
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a reduction of the RHAMM/CD168 antigen by real-
time RT-PCR and a decreased number of CD331 cells
were also noted following vaccine administration.
An example of a widely studied leukemic antigen as
a potential target for immunotherapy is the CML bcr-
abl protein. The fusion region peptide encoded by the
b3a2 or b2a2 translocation is uniquely expressed in
Ph1 leukemia cells, and expression of the protein is es-
sential and sufficient for the development of CML.
The fusion protein results from the reciprocal translo-
cation t(9;22)(q34;q11), which transcribed into 1 of the
most common chimeric bcr/abl mRNA (b3a2), and
translated into BCR/ABL protein (p210 BCR-ABL).
In addition, the protein fusion creates a codon split,
which produces a new amino acid, lysine, in the b3a2
BCR-ABL protein; it is therefore considered as a truly
leukemia-specific antigen. Peptides derived from this
protein were found to bind to a number of HLA
molecules, including HLA-A2, -A3, -A11, and -B8
molecules, and were demonstrated to elicit reactive
T cells in vitro that recognize peptide-pulsed target
cells. Bcr-abl-specific T cells were also detected in
the peripheral blood of b3a2 CML patients and in
some healthy donors. The presence of these tetramer
positive cells in patients was associated with a lower
tumor burden, suggesting that BCR-ABL specific T
cells may participate in disease control. Nevertheless,
ex vivo peptide stimulations were necessary in some
cases to visualize tetramer positive cells and were re-
quired to observe specific cytotoxic activity against
CML targets. In another study, Posthuma et al. [274]
could not detect or induce high avidity BCR-
ABL-specific T cells from a CML patient responding
to DLI. This may, at least in part, be because of the
low affinity of BCR-ABL peptides. Recently, the mod-
ification of amino acid anchor residues in BCR-ABL
peptide sequences showed greater immunogenicity
without loss of original sequence specificity. Immunity
to b3a2 fusion region-derived peptides has also been
elicited in 16 CML patients who received the peptides
with an incomplete Freund’s adjuvant in addition
to imatinib or INF-a. Significantly, cytogenetic re-
sponses, including 2 patients with complete cytoge-
netic responses were observed in patients with
demonstrable immunity [275]. The confounding effect
of receiving additional treatments prevents a clear con-
nection between the induced T cells and the responses,
but future trials are ongoing that will hopefully answer
this important question.
In addition to these T cell target antigens, immuni-
zation withNKT cell epitopes may also be useful either
alone or in combination. The glycolipid antigen a-gal-
actosylceramide (a-GalCer), which binds CD1d, has
demonstrated effective activation of NKT cells [276]
and antitumor activity against a broad spectrum of
malignancies in murine models and humans. Althoughto date most trials using a-GalCer have been conducted
in patients with solid tumors, imatinib-treated CML-
chronic phase patients in complete cytogenetic response
were shown to have NKT cells capable of producing
IFN-g, in contrast to patients in partial remission
[277]. These data, in addition to prior reports demon-
strating CD1d expression by AML cells [278],
provide promising evidence for use of a-GalCer/
a-GalCer-pulsed DC for therapy of AML.
Despite the increasing potential for vaccine devel-
opment for hematologicmalignancies in the allogeneic
HSCT setting, significant hurdles remain for further
development. Although acknowledging there are
more obstacles than those discussed here, we propose
3 broad categories that must be addressed.
First, we do not yet knowwhat constitutes themost
effective vaccine preparation. Should the vaccine be
based on component antigens (DNA, peptide, protein,
or glycolipid), or on whole cells (recipient-derived
leukemia, dendritic cells, or genetically modified
cancer cells) with or without exogenous antigens?
Although antigen-specific approaches have been dis-
cussed, another approach has used lethally irradiated
autologous leukemia cells genetically modified to
secrete GM-CSF [279]. All of these approaches have
yet to be validated in controlled trials in leukemia
patients, however.
Second, we do not yet know when to give vaccines
and which is the most ideal setting to test a vaccine.
There are potential advantages of testing vaccines in
the allogeneic setting because vaccinating recipients
after HSCT offers the opportunity to immunize
a healthy and potentially nontolerized immune system.
This could be the ideal preventative setting if HSCT
recipients are vaccinated in CR or with MRD post-
transplant. Similarly, because leukemia vaccine trials
have shown clinical responses only in patients with
low leukemic burden or MRD [269], this might repre-
sent an ideal clinical situation to test vaccination in
a controlled clinical trial. Although single agents that
target molecular defects yield short-lived responses
without cure in AML [280], and single agents such as
imatinib require continuous treatment to maintain re-
sponse in CML, they might be combined with vaccines
[281,282] to improve clinical outcome. Other agents,
such as decitabine, which can potentially upregulate
antigen expression in leukemia [283], might improve
vaccine effectiveness. In addition, vaccination before
and after lymphodepletion chemotherapy [241], which
may reset homeostatic lymphocyte proliferation, may
yield a more robust immune response in the auto-
logous or allogeneic setting [284].
Third, we need to understand how best to monitor
vaccine interventions for biologic activity. In the case
of T cell antigens, it seems that simply measuring the
number of antigen-specific T cells at specified time
points may not be sufficient to characterize the tumor
Table 2. Summary of Strategies for Prevention of Relapse after Allogeneic Stem Cell Transplantation
Limits of Current Therapy New Strategies Challenges Recommendations
Preparative regimens Toxicity of nontargeted TBI and
chemotherapy limits further dose
intensification and/or selection of drugs
for combinations
Add targeted therapies to reduce toxicities
to nontarget tissues
Heterogeneity of the molecular etiology of
leukemia yields multiple targets.
1. Continue to identify leukemia-specific
therapeutic targets, especially resistance
mechanisms
2. Begin development of these drugs with
current reduced-intensity regimens
Posttransplant drugs Conventional chemotherapy and cytokines
(IL-2) are too toxic for use in the early
post BMT setting
Use targeted therapeutics as maintenance Drug-drug interactions, potential immuno-
or myelosuppression, unclear when it is
best to use these drugs (cancer stem cell
is not cycling)
3. Develop better methods to identify
patients at high risk for relapse
4. Identify strategies for timing treatment to
eliminate the noncyling cancer stem cell
Graft engineering Bulk T cell depletion enhances relapse
potential
Selective depletion of alloreactive cells,
depletion of the naive T cells subset
Insufficient information of which T cell
subsets in humans is responsible for GVH
versus GVL and whether that differs by
MHC-mismatch and leukemia type
5. Additional research into the
identification of human T cell subsets
analogous to those found in mice that
differ in GVH and GVL potential
Donor lymphocyte infusion Treatment efficacy limited to certain
leukemias, efficacy in prophylaxis limited
by GVHD
In the prophylaxis setting, use NK cells,
leukemia-selective CTLs or suicidal CTLs
to get GVL without a great risk of GVHD
Treg may reduce the efficacy of CTLs, there
may be a paucity of targets in the HLA-
identical setting
6. Evaluate methods to eliminate Tregs for
GVL without increasing the risk of
GVHD
T cell tngineering Not available Retarget T cell receptor genetically to
ensure a high proportion with GVL
activity
Leukemias may mediate anti-CTL effects or
have dysregulated apoptosis, CTLs may
not be long lived
7. Identify which T cell subset to retarget to
minimize off-target toxicity but ensuring
they are long lived
8. Add additional molecules to protect
against leukemia counterattack or
elimination by drugs
Vaccine therapies Not available Peptide-based vaccines against leukemia-
selective proteins
HLA-restriction limits applicable population,
optimal dose schedule in humans is
unknown, the leukemia may
downregulate the target protein
9. Identify additional potential targets
10. Develop multivalent polypeptide
vaccine to maximize use across the
MHC
11. Develop NKT immunization to
stimulate innate immunity
Dendritic cell therapies Not available Eliminate the GVHD-inducing DC subset,
use DC subsets that stimulate innate
immunity
DCs are not expected to be effective in the
absence of T cells to be stimulated
12. Better characterize DC subsets and
their role in GVHD and GVL
TBI indicates total body irradiation; NK, natural killer; GVL, graft-versus-leukemia; BMT, bone marrow transplant; CTL, cytotoxic T lymphocyte; GVHD, graft-versus-host disease; DC, dendritic cell; MHC, major
histocompatibility complex.
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of Relapse after AlloHCTimmune response: for example, TCR avidity, measuring
the breadth of the clonal T cell response, and measuring
antigen-specific cytokine production (ELISPOT, cyto-
kine flow cytometry, or bead-based cytokine secretion
assays). Perhaps the most direct, albeit difficult, assay is
to show that antigen-induced T cells or other vaccine-
induced cells specifically lyse malignant cells, and that
they show relative inactivity against nonmalignant cells.
Achieving this critical biologic measurement in a large
number of patients would help advance the concept of
vaccination.
In summary, the strategy of vaccination to induce
GVT offers great potential to be a nontoxic treatment
that can be applied to both donors and recipients to
maximize potential clinical benefit. Challenges re-
main, however. Before realizing the full clinical poten-
tial, we must focus on understanding the most relevant
biological endpoints of effective immunity and not
necessarily the ones that are most easily measured. In
addition to quantitative measures, wemust use qualita-
tive assays that measure cytotoxicity or assays that
directly correlate with cytotoxicity because this is
likely the most relevant biologic event for effective an-
titumor immunity. The setting with perhaps the most
potential for clinical benefit, based on the importance
of GVT and results of early vaccine trials in leukemia,
is in patients with myelogenous malignancies with low
leukemia burden or MRD, such as patients with mo-
lecular disease only. The ideal setting to test vaccines
may be in the setting of secondary prevention, such
as in posttransplant patients at high risk for relapse.
Finally, we do not yet know what components of
a vaccine are most critical for eliciting immunity, but
the identification of mHAgs, leukemia-specific, and
leukemia-associated antigens has yielded many poten-
tial target antigens. Vaccines that direct immunity
against these targets seem most likely to produce
significant results.SUMMARYAND RECOMENDED AREAS OF
INVESTIGATION
Although it is clear that allogeneic HSCT is the
major means for curing patients with hematologic ma-
lignancies, this degree of efficacy is not uniform across
all patients. We have noted that current standard
transplant therapies are limited especially by toxicity.
Selective or targeting tactics, summarized in Table 2,
would be expected to have less toxicity. These strate-
gies include the use of novel targeted drugs that do
not increase toxicity of the conditioning regimen or
interact with other medications taken routinely post-
transplant, selective depletion of the donor graft to
eliminate cells most likely to cause GVHD while
maintaining GVL, prophylactic treatment with T cells
specifically targeting malignant cells and not causingGVHD, and new vaccines that might be applicable
to a broader array of patients than with the single
peptide approach.
Developing these innovative therapies is hampered
by a lack of critical information about the biology of
the human host and the biology of the malignant
cell. We therefore have additional recommendations
(Table 2) to close the knowledge gap regarding
leukemia-specific therapeutic targets, the means to
approach elimination of the noncycling cancer stem
cell, control of Treg subsets, and better characteriza-
tion of the T cell and dendritic cell subsets specific
for GVHD or GVT.
Finally, we also recommend additional epidemio-
logic and biomarker studies, which will be needed to
accelerate clinical development. Studies of therapeu-
tics to prevent relapse are difficult because of the ex-
tended period of time needed to observe the study
endpoint (relapse and/or death). In addition, if the
population is heterogeneous and contains a large
proportion of patients already cured of their disease,
a relatively large number of patients would be needed
in a study to be able to detect a statistically significant
improvement in outcome for the population overall.
Clinical or laboratory factors that identify patients
with a nearly uniform risk for relapse would enrich
the study population and potentially reduce the
number of patients needed to arrive at a meaningful
conclusion. Additionally, identification of biomarkers
followed posttransplant that are direct surrogates for
the study endpoint would enable shorter follow-up
times and allow for progression to the next line of in-
vestigation more rapidly.ACKNOWLEDGMENTS
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